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Voor mam en moeder 
"De wereld der mensheid bezit twee vleugels: 
de mannelijke en vrouwelijke. 
Zolang deze twee vleugels niet even sterk zijn, 
zal de vogel niet vliegen. 
Als de twee vleugels even sterk worden 
doordat zij dezelfde voorrechten genieten, 
zal de vlucht die de mensheid neemt, 
uitermate verheven en uitzonderlijk zijn." 
'Abdu'1-Bahá 
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Chapter 1 
Background and motivation 
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Breast cancer is the most frequent form of cancer in women.1 Recent calculations 
have shown that approximately 10% of the women in the United States will be 
diagnosed with breast cancer before the age of 85 years.2 Table 1.1 shows 
incidence rates in the mid-1980s for several countries.3 After the United States 
and Switzerland, the incidence is highest in the Netherlands with about 73 cases 
of breast cancer cases diagnosed annually per 100,000 woman-years after age-
standardization according to the population of the world. About 1 in 12 women 
will be diagnosed with invasive breast cancer before the age of 75 years. In Table 
1.1, the mortality rates from breast cancer are also shown. Again, the Netherlands 
rank very high, with approximately 27 breast cancer deaths annually per 100,000 
woman-years. Some of the countries with a lower incidence rate than the 
Netherlands, however, have a higher mortality rate, e g the United Kingdom and 
Denmark. In these countries with a higher ratio of mortality to incidence (Table 
1.1), breast cancer is probably diagnosed at a relatively late stage. Early detection 
by screening can be expected to have a larger effect on mortality in these 
countries. 
Table 1 1 Age-standardized (-world population) incidence and mortality rates of female breast 
cancer m selected countries, and ratio of mortality to incidence, ranked by 
incidence rate 
Country Incidence Mortality МЛ' 
United States, Seattle 
United States, Utah 
Switzerland, Geneva 
Netherlands, Eindhoven 
Canada 
Denmark 
Netherlands, Maastricht 
France, Bas Rhin 
Italy, Florence 
Sweden 
Australia, Victoria 
United Kingdom, England & Wales 
Norway 
German Democratic Republic 
Czechia, Slovakia 
India, Bombay 
Japan, Osaka 
rate" 
94 2 
75 4 
73 5 
72 7 
71 1 
68 6 
68 1 
66 3 
65 4 
62 5 
61 7 
56 1 
54 8 
46 3 
34 5 
24 6 
21 9 
rate' 
22 3 
17.9 
27 4 
26 3 
24 2 
27 8 
27 2 
20 6 
20 8 
189 
22 2 
30 3 
187 
182 
188 
88 
64 
(%) 
25 2 
25 2 
42 6 
38 8 
35 6 
46 2 
42 7 
36 7 
35 1 
32 6 
38 5 
59 0 
37 8 
414 
56 2 
35 9 
29 9 
Source "Cancer incidence in five Continents (Volume VI)3" period 1983-1987 
# per 100,000 woman-years 
* ratio of mortality to incidence rate 
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Table 1.2 Number of new cases of breast cancer and number of breast cancer deaths m 1989 
m the Netherlands according to age 
Age at Number diagnosed Number of deaths 
diagnosis/death 
(years) 
< 50 2049 ( 26%) 
50-69 3392 ( 43%) 
70+ 2527 ( 32%) 
Total 7968 (100%) 
Source the Netherlands Cancer Registry4 
Table 1.2 shows the number of newly diagnosed cases and the number of breast 
cancer deaths in the Netherlands in 1989, in 3 age categories.4 In the whole 
population, there were almost 8000 newly diagnosed cases of breast cancer, one 
third of them were 70 years or older. The number of deaths from breast cancer 
was almost 3400. Approximately half of the deaths from breast cancer occurred 
in patients aged 70 years or older. 
In 1963, the first trial on the effectiveness of breast cancer screening was started. 
The research question in this Health Insurance Plan (HIP) trial in Greater New 
York was whether breast cancer mortality could be reduced by annual screening 
with two-view mammography combined with physical breast examination.5 For 
the study, 62,000 women aged 40-64 years were allocated at random in the ratio 
1:1 to one of two groups who received an invitation for screening or not. The 
results reported in 1971 were promising: 31 deaths from breast cancer in the 
study group compared to 52 in the control group. 
The high mortality rate in the Netherlands and the promising results of the HIP 
study formed the motivation to seek financial support for a screening project in 
Nijmegen.6 The project was organized with a grant from the Prevention Fund in 
order to study the effect of population screening for breast cancer with modem 
mammography (i.e. using dedicated mammography equipment with a molyb-
denum anode and a so-called low-dose film-screen combination) as the only 
screening method. The project was started in 1975 with biennial one-view 
mammography for women aged 35 years and older. After 6 years of follow-up, 
the effect of screening on breast cancer mortality was analysed by means of 
comparing the mortality rate in the participants to that in the non-participants 
(using the so-called case-referent or case-control method).7 Beast cancer mortality 
in the women who did participate was 52% lower than in those who did not 
454 ( 14%) 
1283 ( 38%) 
1628(48%) 
3365 (100%) 
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participate.8 The 95% confidence interval (CI) was 0%-77% reduction. The 
underlying incidences in the self-selected populations of screened and unscreened 
women were estimated to be the same. With an additional year of follow-up, the 
reduction in breast cancer mortality was 49% (95% CI l%-74%).9 
In the meantime, several other studies, including some randomized controlled 
trials in the United States and Europe, have also demonstrated a screening-related 
reduction in breast cancer mortality with different screening methods (e.g. one 
or two-view mammography sometimes combined with physical examination) and 
different intervals between screening rounds (one, two or three years).10"13 
Extensive meta-analyses of the results of these studies have lead to the conclusion 
that in the whole population of women aged 50-70 years, mortality from breast 
cancer can be reduced by about 30%.14"17 In participants, the reduction may be 
as large as 45%.18 Screening seemed to be effective at least up to the age of 75 
years, but more research was needed to confirm this.15·19·20 
In 1989, a national breast screening programme was started in the Netherlands 
for women aged 50 to 70 years. Women who reached the age of 70 years were 
permitted to continue to participate at their own request.21 From 1993 onwards, 
however, women aged 70 years or older were excluded from the screening 
programme. The motivations for this decision were the absence of any evidence 
that screening had a beneficial effect in this age category and concern that 
negative side-effects may outweigh the possible positive effect.22 Abroad, there 
is no consensus either about the upper age limit for breast cancer screening.15·20·23 
In various countries that promote screening for breast cancer, the guidelines for 
an upper limit vary from 64, 69, 74, 84 years to no age limit, i.e. up to a very 
advanced age in women with a good general life expectancy.2325 
The decision about whether or not to set an upper age limit, and at what age, 
should be made by carefully balancing the effects against the side-effects. 
However, little is known about the extent of most (side-) effects. Worldwide, 
only two trials have systematically invited elderly women: the randomized two-
county trial in Sweden and the Nijmegen screening project.8·26 In the former 
study, women aged 70 and older at the start of the trial received invitations for 
two screening rounds. Results have been reported for women of up to 74 years, 
but the older women were excluded from the analyses because the participation 
rate was considered to be too low (51%). 
The purpose of the present study was to investigate whether screening of women 
aged 65 years and older affects the stage at diagnosis and breast cancer mortality. 
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The setting for the various studies described below is the Nijmegen screening 
project. It is the only long-term project in the world that includes elderly women. 
Chapter 2 is a review of the literature on the anticipated effect of screening in 
elderly women. The relation between age and epidemiological and biological 
factors of breast cancer are discussed, as well as the impact of these factors on 
mammography as a screening test. Furthermore, the screening-related mortality 
reduction in studies that included elderly women was examined. 
Chapter 3 presents studies on the validity of mammography as a screening test 
for breast cancer. To determine the detectability of breast cancer by modern 
mammography, the previous negative screening mammogram of a group of 
screen-detected patients and interval cancer patients was reviewed. These 
mammograms were checked for the presence of signs and whether they were 
considered as mammographie signs for breast cancer. Chapter 3 also deals with 
the quality of one-view mammography compared to two-view mammography for 
initial screening. To achieve a reduction in breast cancer mortality, the sensitivity 
of the screening test must be optimal, that is, most of the cancers should 
preferably be detected in their preclinically detectable phase. At the same time 
the specificity should be high to prevent healthy women from being referred for 
unnecessary further diagnostic tests. This issue was addressed by means of 
reviewing the literature. 
Chapter 4 describes the early outcomes of mammographie screening in elderly 
women, such as the number of screen-detected cancers per 1000 women and their 
stage at diagnosis. Chapters 5 and 6 deal with the key issue: does screening 
elderly women affect breast cancer mortality. In the two studies outlined in 
Chapter 5, a case-referent design was used, comparing breast cancer mortality 
between women who participated in the screening and those who did not. These 
two studies differed with regard to the length of follow-up and the definition of 
the relevant screening histories. The final discussion section of the Chapter 
addresses the differences between the screening histories as well as the impact of 
bias due to self-selection. Chapter 6 makes a comparison between breast cancer 
mortality in the invited population from Nijmegen, regardless of participation, 
and that in an unscreened population from the neighbouring city of Arnhem. This 
design was used to avoid self-selection bias. Chapter 7 reviews the evidence and 
formulates issues for future research. 
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Screening for breast cancer after the age of 70 years: 
a further reduction in breast cancer mortality? 
JAAM van Dijck, ALM Verbeek, JHCL Hendriks, R Holland 
Introduction 
The Dutch national screening programme for breast cancer was set for women 
aged 50 to 70 years. Once a woman had reached the age of 70 years, she was 
permitted to continue participating if she wished. In 1993, however, the latter 
policy was halted because the cost of the programme was exceeding the 
budget. Arguments included uncertainty about a possible reduction in breast 
cancer mortality by screening older women. Furthermore, there would be 
more negative side-effects, such as an increased number of person-years that a 
woman would have to live with the knowledge that she has the disease. This 
applies especially to screen-detected breast cancer patients who would die of 
another disease before the breast cancer would otherwise have been diagnosed 
on clinical grounds.' 
There is still no consensus about the upper age limit for breast screening in 
the Netherlands and abroad. In the various countries, guidelines vary from no 
upper age limit to an upper limit of 64, 69, 74 or 84 years.2 A forum "On 
breast cancer screening in older women" recommended that annual physical 
examination and biennial mammography should be continued up to the age of 
75 years and up to a very advanced age in women with a good general life 
expectancy.3 
In the following sections, epidemiological and biological aspects of breast 
cancer in elderly women are discussed. Besides, results of several trials on the 
effectiveness of screening are being reviewed, especially the Nijmegen pro-
gramme which started in 1975 with biennial mammography for women aged 
35-65 years. From the second round (1977) and on also women over age 65 
were invited. 
Epidemiology 
Incidence 
For several decades, the age-specific incidence of breast cancer has been 
rising worldwide, especially among elderly women. Further increases in the 
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1980s in both the United States and the Netherlands were attributed to an 
increase in the use of mammography.4 Figure 2.1 shows the age-specific num­
bers of newly diagnosed breast cancers and deaths from breast cancer per 
100,000 women in 1989 in the Netherlands.5 In that year, almost 8000 invas­
ive breast cancers were diagnosed; 25% of the patients were younger than 50 
years, 43% were aged 50-69 years and 32% were 70 years and older (Table 
2.1).5 Owing to the increasing proportion of older women in the population, it 
is expected that the number of newly diagnosed cases of breast cancer will 
increase further to over 11,000 in the year 2010 (Table 2.1). 
Figure 2.1 Incidence (A) of breast cancer and mortality (B) in the Netherlands per age 
category, 19895 
400 
No. per 105 person-years 
300 
200 
100 
0-ψ 
Age in years 
It has been suggested that the incidence of breast cancer in elderly women 
who were regular participants in the breast screening becomes so low that it no 
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longer justifies continuation of the screening. However, the opposite can be 
seen in Table 2.2, which shows the detection rates among screened Nijmegen 
women aged 70 and older. At the first screening (round 2 for this age cat-
egory) about 10 breast cancers were detected in 1000 screened women. At 
successive screenings, the detection rate stabilized at about 8 cancers per 1000 
screened women. 
Table 2.1 Number of newly diagnosed cases of breast cancer per age category (at 
diagnosis) in 1989 and the predicted numbers in 2000 and 2010 
Age at 
(years) 
<50 
50-69 
70+ 
Total 
diagnosis Number of newly diagnosed breast cancers in 
1989* 
2,049 (25%) 
3,392 (43%) 
2,527 (32%) 
7,968 (100%) 
2000f 
2,371 (26%) 
3,893 (42%) 
3,021 (33%) 
9,285 (100%) 
2010t 
2,456 (23%) 
4,775 (45%) 
3,285 (31%) 
10,516 (100%) 
* Source: the Netherlands Cancer Registry 1989 (5) 
f
 Age-specific incidence rate in 1989 applied to the midvariant of the population prog-
nosis of the Dutch Central Bureau of Statistics (1989) 
Table 2.2 Detection rates per screening round of the Nijmegen programme in the age 
category 70 years and older at invitation 
Screening- Number of women Number of screen- Detection rate per 1000 
round* screened detected cancers screened women 
2 2,288 23 10.1 
3 1,783 12 6.7 
4 1,711 15 8.8 
5 1,672 11 6.6 
6 1,898 16 8.4 
7 2,069 17 8.2 
8 1,936 14 7.2 
9 1,274 12 9.4 
* Round 2 was the first screening for women aged 70 years and older, while the subse-
quent rounds concerned almost exclusively successive screenings 
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Life expectancy 
Life-tables of the Dutch Central Bureau of Statistics (CBS) show that in 1991, 
the life expectancy of 70 and 80-year-old women was about 15 and 8 years, 
respectively. Life expectancy reflects the risk of dying at a certain age and 
depends on the presence of chronic comorbid disease. A healthy 70-year-old 
woman can be expected to live longer than the 15 years that are expected for 
all 70-year-olds. 
Biological aspects 
Breast tissue 
Growing older is associated with physiological changes in the breast; these 
actually facilitate the detection of abnormalities with mammographie screen­
ing. After the menopause, the glandular tissue is gradually replaced by fat. 
Due to the fact that fat absorbs less radiation than glandular tissue, there will 
be greater contrast between breast tissue and tumour tissue, which increases 
the sensitivity of mammography. Moreover, the frequency of benign breast 
disease is lower, which increases the chance that a newly developed lesion 
shadow on the mammogram will be a carcinoma. This may in tum increase 
the specificity. 
Table 2.3 Results of the Nijmegen programme for two age categories. Mean values of 
the results of rounds 4-9 
Result 
Rate of screen-detected cancers 
Rate of interval cancers*1. 
Referral rate 
Sensitivity*1 
Specificity 
Positive predictive value of referral 
Positive predictive value of biopsy 
Age at invitation 
50-69 yrs 
3.6 %, 
2.1 °/oo 
6.2 о/«, 
62.4 °/0 
99.7 °/0 
59.0 °/0 
70.4 °/0 
70+ yrs 
8.1°/oo 
3.3 "/co 
12.2 0IW 
70.1 °/0 
99.6 °/0 
68.3 °/0 
79.8 °/0 
* Interval cancer diagnosed within 2 years of a negative screening result 
1
 Average of rounds 4-8 
* Sensitivity = (screen-detected cancers)/(screen-detected + interval cancers) 
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Table 2.3 shows the average values for several characteristics of Nijmegen 
screening mammography in rounds 5 to 9. These rounds almost exclusively 
concern successive screening. Sensitivity, calculated as the percentage of 
screen-detected cancers versus the sum of screen-detected and interval cancers, 
was slightly higher for women aged 70 years and older. This was also true for 
the predictive values for referral and biopsy. (Interval cancers are diagnosed 
clinically after a negative screening result, but before the next invitation 2 
years later). Specificity was roughly the same for the respective age 
categories. 
Tumour biology 
The biological characteristics of breast cancer are prognostically better in older 
women than in younger ones. This is due to better histological differentiation 
and a larger proportion of the tumours are positive for oestrogen and proges-
terone receptors.6 Furthermore, the growth rate of breast cancer is slower in 
older age. In the Nijmegen screening patients, tumour volume doubling times 
were calculated from the tumour sizes measured on serial mammograms. The 
median doubling time was 80 days in patients of younger than 50 at diagnosis, 
157 days in patients aged 50-70 years and 188 days in patients older than 70 
years.7 Due to the slower tumour growth rate, which also contributes to the 
higher sensitivity of mammography, breast cancer can be diagnosed at an even 
earlier stage. For women aged 50-70 years, the lead-time has been estimated 
at 3.5 years. Due to the small difference in growth rate between the age 
categories 50-69 and >70 years, the lead-time will be about 4 years. 
Disease-specific survival 
In several studies, disease-specific survival was slightly poorer for older breast 
cancer patients.8·9 This was mainly caused by the more advanced stage of the 
disease at diagnosis; elderly patients were more prone to having a large 
tumour and distant metastases.5·8"10 Survival is also influenced adversely by the 
presence of (several) comorbid diseases and a poor physical condition.911 The 
effect of early diagnosis may even be lost in breast cancer patients with ser-
ious comorbidity, who have an increased risk of dying from causes other than 
breast cancer.11 Furthermore, it is the general trend to perform fewer opera-
tions or less extensive operations on older breast cancer patients and to 
administer hormone therapy as adjuvant treatment instead of radiotherapy. A 
large proportion of these patients receive hormone therapy alone.8·9·11 Less 
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intensive treatment, however, does not seem to influence the disease-specific 
survival.9 
Owing to the slower growth rate of breast cancer in older women, the 
diagnosis can be brought forward even further. If this results in a smaller 
proportion of patients with positive axillary lymph nodes at diagnosis, the 
reduction in breast cancer mortality may increase. However, as more patients 
will die from unrelated causes, the increase in life expectancy may be only 
minimal. Even if life expectancy is unchanged, some patients will benefit from 
screening, for example in terms of quality of life. This applies to patients 
who, without screening would have had distant metastases at diagnosis, but 
who die without metastases because of screening. 
The combination of a slower growth rate and the shorter life expectancy 
will have a negative effect on the side-effects of the screening. Women who, 
without screening would not have been diagnosed with breast cancer because 
they died of another cause in the preclinical phase of breast cancer, will be 
confronted with the diagnosis breast cancer and possibly even be treated. The 
increase in the number of years lived with the knowledge that breast cancer is 
present may be even larger than the number of life years gained. 
Studies on the effect of screening 
Several studies have investigated the effect of mammographie screening on 
breast cancer mortality and many reviews of the available evidence have been 
published. Generally, it is concluded that in women aged 50 to 70 years, 
mammographie screening with or without palpation with an interval of one or 
two years, reduces breast cancer mortality,12"15 while for invited women, the 
reduction in breast cancer mortality is estimated to be 23 to 40%.12"14 For 
participants, the reduction may be as large as 45%.n The few authors that 
reviewed screening in elderly women concluded that screening may be effec-
tive up to the age of 75 years, but that more research is needed to confirm 
this.15·16 
Table 2.4 shows the most important characteristics and results of Dutch 
screening projects and those of foreign studies that included women aged 70 
years and older. The results suggest that, although not statistically significant 
due to the small numbers of screened women, screening after the age of 70 
had a beneficial effect. It should be noted, however, that in most studies, age 
was defined as age at entry into the trial or age at diagnosis. 
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This does not necessarily correspond with age at the screening examination. 
The reduction in breast cancer mortality in women aged 50-69 years at entry 
may be partly due to screening after the age of 69 years. 
Methods used to analyse the screening histories leave much to be desired. 
The randomized trials compared breast cancer mortality in the invited popula-
tion to that in the non-invited population.17·18 Participation rates had a very 
strong influence on the results. The reduction in breast cancer mortality among 
the screened women will be larger than among invited (participant and non-
participant) women. The case-control studies compared breast cancer mortality 
in "ever screened" and "never screened" women.19·20·22 "Ever screened", how-
ever, may have meant that a woman rejected the screening in the period that 
the disease was in the preclinical detectable phase, which would have reduced 
the effect. 
Misclassification of the end-point, "death due to breast cancer", may bias 
the results. Older women often have comorbid disease, which complicates the 
classification of the cause of death. This may lead to underestimation of the 
real effect of screening. Breast cancer as an underlying cause of death may be 
over-reported in screened women, because the disease did not go unnoticed 
and therefore may be regarded as the cause of death. In the overview of the 
Swedish trials, the end point used was "breast cancer present at death". 
Although it was shown that the results were the same whether this end point 
was used or "death due to breast cancer",18 there may have been a discrepancy 
in the elderly women because of the increased risk of death from another 
cause, with or without breast cancer. This may be an explanation for the 
disappointing results after 13 years of follow-up in women aged 70-74 years at 
randomization (a reduction in breast cancer mortality of 6%).18 After 8 years, 
a reduction of 23% was found for the end-point "death due to breast cancer".17 
Continuation of the screening 
The most important question for the Dutch national programme, i.e. whether 
continuation of screening after the age of 70 years will further reduce breast 
cancer mortality, has been studied recently in the Nijmegen programme.23 A 
case-referent study was conducted on 33 cases who had died from breast 
cancer and five referents per case with an identical age at their first invitation 
and the same number of previous invitations. Eligibility criteria were having 
been invited at least twice before the diagnosis of breast cancer and age over 
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64 years at the most recent invitation. In the women aged 65-74, breast cancer 
mortality in the women who had participated just prior to the diagnosis of the 
case, relative to those who had not, was reduced by 66% (rate ratio = 0.34, 
95% CI 0.12-0.97). Participation before and after the age of 65 years relative 
to participation before the age of 65 only, was associated with a reduction of 
74% (rate ratio 0.26, 95% CI 0.05-1.32). In participants before and after the 
age of 70 years relative to participants before the age of 70 only, the reduction 
was 62% (rate ratio 0.38, 95% CI 0.03-4.15). Additional analyses showed 
that self-selection bias was present in the data. Non-participants (diagnosed 
after the start of the screening) had a lower mortality rate from breast cancer 
than was expected on the basis of the Arnhem mortality data. The underlying 
breast cancer mortality in the participants must have been higher. Therefore, 
the self-selection bias could not explain our results. It was concluded that 
continuation of mammographie screening up to the age of 75 years may fur-
ther reduce breast cancer mortality, whereas the effect of continuation after 75 
years remains unclear. 
Table 2.5 Participation rates in round 9 of the Nijmegen programme accord-
ing to age at invitation 
Age at 
invitation to round 
9(yrs) 
40-49 
50-59 
60-69 
70-74 
75-79 
80 + 
AI1 invited 
no. 
invited 
3,841 
7,499 
6,807 
3,340 
2,042 
2,906 
I women 
no. 
screened 
2,621 
5,114 
4,192 
806 
296 
172 
partici-
pation 
68.2% 
68.2% 
61.6% 
24.1% 
14.5% 
5.9% 
Women who had also partici-
pated in 
no. 
invited 
2,741 
5,154 
4,267 
1,605 
683 
337 
round 8 
no. 
screened 
2,322 
4,499 
3,692 
710 
246 
114 
partici-
pation 
84.7% 
87.3% 
86.5% 
44.2% 
36.0% 
33.8% 
Total 26,435 13,201 50% 14,787 11,583 78% 
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Participation 
The participation rate in breast screening decreases with increasing age. A 
variety of factors may be responsible for this. An important one may be the 
presence of comorbid disease, which decreases a woman's motivation and 
mobility and dampens her expectations. Table 2.5 shows the Nijmegen parti-
cipation rates in round 9 according to age at invitation. These rates decrease 
sharply with increasing age. However, participation was much higher in the 
women who participated in the previous round. 
Cost-effectiveness 
De Koning and colleagues24 calculated that in the Netherlands, biennial 
mammographie screening of women aged 50-70 years will cost 466 million 
Dutch guilders in the period 1990-2017. If women aged 70-75 years are 
included in the target population, the cost will increase by Dfl 64 million.24 
The cost divided by the number of life years gained gave a cost-effect ratio of 
roughly Dfl. 7650 and Dfl. 8200 per life year gained for the first and second 
alternatives, respectively. The cost for each quality adjusted life year gained 
was estimated to be Dfl. 8100 and Dfl. 8900, respectively.24 
However, the higher cost per life year gained by screening after the age of 
70 years may not be a valid argument for establishing an upper age limit, 
because it encourages age discrimination.25·26 It should be considered whether 
the total cost of expanding the target population would make to high a claim 
on the total budget for the health service and obstruct the implementation of 
other health facilities. 
Conclusion 
The incidence of breast cancer is highest among women aged 70 years and 
older. Compared to younger women, elderly women are more likely to have 
distant metastases at diagnosis and the disease-specific survival of disseminated 
breast cancer seems to be poor. Even if breast cancer is diagnosed at an early 
stage, it will not improve the survival of patients with several chronic co-
existing diseases. 
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The value of screening for breast cancer in women of over 70 years depends 
on several factors. In this age category, mammography is a good screening 
test. Trials indicate a possible breast cancer mortality reduction due to (the 
continuation of) biennial screening up to the age of 75 years. The magnitude 
of the mortality reduction, however, remains unclear. 
Owing to the shorter life expectancy and a slower tumour growth rate, over-
diagnosis and over-treatment may occur. The number of years that a woman 
has to live with the knowledge that she has breast cancer may increase even 
more than the number of life years gained. A longer screening interval (e.g. 3 
years) may reduce both the cost and side-effects. 
In women with several comorbid diseases, screening for breast cancer will 
not improve survival. It is very likely that selective participation will occur: 
mainly the women in whom benefit can be expected, will continue to partici-
pate. Lack of evidence prevents us from drawing any conclusions about how 
long they should continue to participate. 
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Introduction 
In Chapter 2, the effect of increasing age on the quality of mammography as a 
screening test was outlined. The sensitivity may increase in the elderly because 
glandular tissue is gradually replaced by fat, while the specificity may increase 
because the frequency of benign breast disease is lower. This Chapter presents 
a study on the detectability of breast cancer with mammography, published in 
Cancer 1993; 72: 1933-8. Previous negative mammograms of screen-detected 
patients and interval cancer patients were reviewed. It was recorded whether 
or not mammographie signs of the cancer were visible on the previous, 
negative, mammogram, and if so, whether or not the signs could have led to 
the diagnosis of breast cancer. At the end of this Chapter, in the section "Age-
specific detectability" (page 53) the relation between age at screening and the 
classification of the previous mammogram is discussed. 
Usually, signs of benign breast diseases are also visible on a mammogram, 
but it may be very difficult to discriminate between "benign" and "malignant" 
signs. This results in the referral of women without breast cancer for diagnos-
tic work-up, which reduces the specificity of mammographie screening. Both 
the sensitivity and the specificity may increase if two-view mammography is 
used instead of one-view. However, the financial cost and the exposure to 
radiation will also increase. The literature was reviewed on the effect of one-
view and two-view mammography in baseline screening (The British Journal 
of Radiology 1992; 65: 971-6). This study in perspective with very recent 
publications on the subject is also included in this Chapter (page 42 and page 
54, respectively). 
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The current detectability of breast cancer in a mammo-
graphie screening programme: A review of the previous 
mammograms of interval and screen-detected cancers 
JAAM van Dijck, ALM Verbeek, JHCL Hendriks, R Holland 
Abstract 
The occurrence of an interval cancer in a mammographie screening 
programme is indicative of a suboptimum effect on mortality, because the 
very aim of the screening is to detect as many cancers as possible and at 
their earliest possible stage. In several studies, the previous screening 
mammograms of patients with an interval cancer were reviewed and the 
reasons for the "missed diagnosis" were classified into four categories: 
"screening error" (20-29%), "minimal sign present" (30-40%), "radio-
graphically occult" (33-58%), or "radiographically occult at diagnosis" 
(occult both at previous screening and diagnosis; 7-16%). A similar 
procedure was followed in the Nijmegen screening project with patients 
recently diagnosed as having interval cancer or screen-detected cancer. 
The previous screening mammograms of 40 interval and 44 screen-
detected cases from the breast cancer screening programme in Nijmegen 
were reviewed and categorised as specified above. These breast cancers 
were diagnosed clinically before the patient was invited to the eighth 
screening round (interval cancer) or were detected at the eighth screening 
round (screen-detected cancer). All these patients had been screened in the 
seventh round (1987-88). 
Thirteen percent of all cases were classified as "screening error", 38% 
as "minimal sign present", 43% as "radiographically occult", and 6% as 
"radiographically occult at diagnosis". In nearly half of the screen-
detected cancers, minimal signs appeared to be present on the previous 
screening mammogram 2 years befor the diagnosis. 
Annual instead of biennial screening may advance detection in most of 
the "screening error" cases as well as in some in the categories "minimal 
sign present" and "radiographically occult" at the previous screening. 
Meticulous analysis of the radiological characteristics of the "minimal sign 
present" cases may very well lead to results showing that earlier detection 
is possible without a significant decrease in the specificity of the screening 
test. 
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Introduction 
Over the past few years, the technical quality of mammography, currently the 
most reliable screening test for the early detection of breast cancer,1 has been 
improved considerably. This apparently increased the number of breast cancer 
cases detected and decreased the number of cancers missed at the screening. 
Consequently, this development may have had a bénéficiai effect on breast 
cancer mortality. 
So far, only the results of studies on interval cancers, that is, cancers which 
were clinically diagnosed after a "negative" screening examination and before 
the next scheduled screening, have been reported. Reasons for the missed 
diagnosis of these cancers were revealed by a review of the "negative" 
mammograms taken at the previous screening examination.2"6 They were 
classified as screening errors, minimal or non-specific sign present, radio-
graphically occult, and radiographically occult both at the previous screening 
and at diagnosis (Table 3.1). This classification of the previous "negative" 
screening mammograms can also be applied to the screen-detected cases, with 
the exception of the category "radiographically occult at diagnosis", if 
mammography is the sole screening test. 
Table 3.1 Classification of previous screening mammograms of patients with interval 
cancer in the literature 
Reference 
Martin et al.3 
Von Rosen et al.4 
Frisell et al.5 
Peeters et al.6 
No. of 
cases 
48 
42 
60 
153 
Classification of previous screening mammograms 
Screening 
error 
(%) 
29 
24 
20 
26 
Minimal 
sign 
(%) 
38 
33 
28 
— 
Radiograph 
occult 
(%) 
33 
36 
52 
58 
Radiograph 
occult at 
diagnosis (%) 
— 
7 
— 
16 
In the current study, we reviewed the previous "negative" screening 
mammograms of patients with recently diagnosed breast cancers. The study 
population comprised, in addition to the interval cancers, the screen-detected 
cases of the Nijmegen screening programme. 
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Patients, mammograms, and methods 
Since 1975, a population-based mammographie breast cancer screening has 
been in progress in the city of Nijmegen, The Netherlands. Single-view 
mammography is applied biennially as the only screening modality. Results of 
the first six screening rounds have been reported earlier.7 
The objective of the current study was to review the previous screening 
mammograms of recently diagnosed breast cancer patients. Two groups of 
patients were studied. The first group comprised 41 interval cancer cases that 
had been clinically diagnosed with primary breast cancer after a negative 
screening result in the seventh round (1987-88), but before their invitation to 
the eighth round. One of these patients had to be excluded because both the 
mammogram and the report were no longer available. The second group 
consisted of 57 primary breast cancer cases that were detected on the 
mammogram taken in round 8 (1989-90). Thirteen cases were excluded 
because they had not attended the screening in round 7. Patients with the sole 
histologic tumor type of "lobular carcinoma in situ" were also excluded. Thus, 
a total of 84 patients was studied. 
The mammogram at diagnosis of each patient was reviewed by the radi-
ologist (JH). (In four cases the mammogram was missing and only the report 
was available.) Then the previous mammograms, taken during the seventh 
screening examination, were reviewed with knowledge of the site and 
radiologic signs of the tumor. The cases were classified into one of the follow-
ing four groups: 
Screening error: (1) if malignant signs were present that had not been 
perceived or had been misinterpreted (i.e., present but interpreted as 
benign); (2) if the tumor, visible at diagnosis, had been outside the imaging 
field because of faulty positioning; or (3) if the malignant signs could not 
have been noticed because of a technically poor mammogram. 
Minimal sign present: if a radiological sign had been observed that was 
considered to be nonspecific for the presence of a malignant tumor (i.e., 
that it did not necessitate a further diagnostic evaluation). 
Radiographically occult: if no changes at all could be seen on the 
previous mammogram. 
Radiographically occult at diagnosis: if no signs suspicious of malig 
nancy could be identified on both the diagnostic and the previous screening 
mammogram; these cases were detected by physical examination. 
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At the review, the radiologic characteristics such as tumor localization and 
size, as well as the density of the breast parenchyma according to Wolfe's 
classification,8 were recorded. The screening history and histologic character-
istics of the tumor were available from the screening and hospital files. 
Results 
Thirteen percent of the previous mammograms (Table 3.2) were classified as 
"screening error", 38% as "minimal sign present", 43% as "radiographically 
occult" and 6% as "radiographically occult at diagnosis". 
The categories are outlined separately below. 
Table 3.2 Classification of previous screening mammograms of 84 patients with breast 
cancer 
Classification of previous mammogram 
No. of Screening Minimal Radiograph Radiograph 
Group cases error sign present occult occult at 
(%) (%) (%) (%) diagnosis (%) 
All cancers 84(100) 11(13) 32(38) 36(43) 5(6) 
Interval cancer 40(100) 7(18) 11(28) 17(42) 5(12) 
Screen-detected 44 (100) 4(9) 21 (48) 19 (43) Not applicable 
cancer 
Screening Error 
In 11 patients, the diagnosis had been missed as a result of errors made in the 
screening process. In two of them, technical errors had been responsible, due 
to poor positioning in one case and poor technical quality in the other. In the 
remaining nine cases, one lesion had been misinterpreted, whereas eight 
lesions had not been perceived. Table 3.3 shows the radiologic signs present 
on the patients' previous mammograms. Most of them had a tumor mass with 
a malignant appearance. All the cancers were invasive and 55% of the patients 
had axillary lymph node involvement (Table 3.4). 
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Table 3.3 Radiologic signs on the previous screening mammogram for "screening 
error" and "minimal sign present" 
Radiologic sign 
Vague density 
Density 
Microcalcifications 
Density + microcalcifications 
Distortion of architecture 
Total 
Classification of 
Screening error 
(%) 
7(70) 
2(20) 
0 ( 0) 
1(10) 
10 (100)* 
previous mammogram 
Minimal sign 
present (%) 
15 (47) 
5(16) 
8(25) 
К 3) 
3 ( 9) 
32 (100) 
* One value missing because of poor positioning 
Minimal Sign Present 
Twenty-eight percent of the patients with interval cancers and 48% with 
screen-detected cancers showed minimal signs on the previous screening 
mammogram (Table 3.2). 
At diagnosis, these tumors appeared to be larger and had a higher preval­
ence of axillary node involvement than those classified as "radiographically 
occult" (Table 3.4). 
Table 3.3 shows the type of radiologic signs visible on the patients' previ­
ous mammograms, the majority of which (almost 50%) consisted of vague 
densities. 
Radiographically occult 
Forty-three percent of the tumors (Table 3.2) were "radiographically occult" 
on the previous mammogram. Some tumors in this category must have been 
fast growing and therefore may have been smaller than the threshold size of 
radiologic detection, whereas others may have been masked by dense breast 
tissue.9 Nevertheless, many of these tumors were located in fatty tissue (61%), 
suggesting a fast growth. 
The tumor stage at diagnosis in this category was the most favorable: 31% 
of the tumors had a diameter of 1 cm or less at diagnosis, compared to only 
9%, 11% and 0% in the other categories, respectively (Table 3.4). Axillary 
node involvement was 31% and almost 50%, respectively (Table 3.4). 
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Table 3.4 Characteristics of tumor and breast parenchyma in 84 breast cancer patients 
by review category 
Characteristic 
No. 
Interval cancer 
Screen-detected cancer 
Tumor 
Main sign on diagnostic mammogram: 
Density 
Microcalcifications 
Density + microcalcifications 
Distortion of architecture 
Histologic type: 
Ductal in situ 
Ductal invasive 
Lobular invasive 
Other 
Tumor size on diagnostic mammogram 
(mm)*·1: 
<10 
11-20 
>20 
Axillary lymph nodes": 
Positive 
Negative 
Breast parenchyma 
Wolfe previous mammogram: 
N1, PI 
P2, DY 
Total 
(%) 
84 
40 (48) 
44(52) 
79 
50 (63) 
13 (16) 
10 (13) 
6 ( 8 ) 
83 
9(11) 
52 (63) 
15 (18) 
7 ( 8 ) 
74 
14 (19) 
32 (43) 
28 (38) 
74 
31 (42) 
43 (58) 
84 
45 (54) 
39 (46) 
Classification of previous mammogram 
Screening 
error 
(*> 
11 
7(64) 
4(36) 
8(73) 
0 ( 0) 
2(18) 
1( 9) 
0 ( 0) 
8(73) 
2(18) 
К 9) 
К 9) 
4(36) 
6(55) 
6(55) 
5(45) 
5(45) 
6(55) 
Minimal 
sign 
present 
(%) 
32 
11 (34) 
21 (66) 
20 (63) 
7(22) 
4(13) 
1 ( 3) 
5(16) 
19 (59) 
6(19) 
2 ( 6) 
3(11) 
12 (44) 
12 (44) 
13 (48) 
14 (52) 
16 (50) 
16 (50) 
Radio­
graph 
occult 
(%) 
36 
17 (47) 
19 (53) 
22 (61) 
6(17) 
4(11) 
4(11) 
4(11) 
23(64) 
5(14) 
4(11) 
10 (31) 
14(44) 
8(25) 
10 (31) 
22 (69) 
22 (61) 
14 (39) 
Radiog­
raph 
occult at 
diagnosis 
(%) 
5 
5(100) 
0 ( 0) 
— 
— 
— 
— 
0 ( 0) 
2(50) 
2(50) 
0 ( 0) 
0 ( 0) 
2(50) 
2(50) 
2(50) 
2(50) 
2(40) 
3(60) 
" Invasive tumors only. 
* Histologic tumor size if no mammographie size could be measured. 
Radiographically occult at diagnosis 
This category comprised 6% of all the cases. Their histologic type was "invas­
ive ductal" (n = 2) or "invasive lobular" (n = 2). It is known that these latter 
are difficult to detect by mammography owing to their diffuse growth pattern 
and poor desmoplastic reaction.9 The two lobular carcinomas were situated in 
breast tissue classified as Wolfe's N1 and PI, whereas the two ductal 
carcinomas were situated in PI and P2 breast parenchyma, respectively. 
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At diagnosis, the tumors were large and had a high prevalence of positive 
axillary nodes (50%). This advanced stage may have been due to the late 
diagnosis because of the shortcomings of the mammographical technique in 
these types of cancer. They might very well remain undetected at the screen-
ing unless palpation were part of the test. 
Discussion 
Currently, mammography is the most valuable test for diagnosing early breast 
cancer, especially if it is applied at regular intervals within a screening pro-
gramme.1 False-negative screening test results (i.e., negative results despite of 
the presence of malignant signs that should have been noticed) cause a delay in 
treatment and may jeopardize the effectiveness of the screening. It has been 
recognized that interval cancers may represent potential false-negative results,2" 
4.6,10
 whereas screen-detected cancers always were considered to be the true-
positive results. In the current study of the Nijmegen breast cancer screening 
programme, the previous mammograms of the patients not only with interval 
cancers but also with screen-detected cancers were reviewed and categorised. 
In 9% of the screen-detected patients, the previous screening result was true 
false-negative (classified as "screening error" in Table 3.2) which had delayed 
the diagnosis by two years. 
Since the introduction of breast cancer screening in Nijmegen in 1975, both 
the experience of the radiologist in reading mammograms and the technical 
quality have increased considerably. This should have improved the detection 
capability and reduced the occurrence of interval cancers. The detection rates 
of the successive screening rounds since 1975, however, have not increased, 
nor the proportion of interval cancers declined (Table 3.5). An explanation 
may be that although more lesions become visible because of the improved 
resolving power of the mammography, our criteria for referral for diagnostic 
evaluation have become stricter as a consequence of our policy to reduce the 
number of false-positive results. This assumption is supported by the increase 
in the specificity rates (calculated according to Brecht and Robra") over the 
progressive screening rounds (Table 3.5). 
In our earlier study on interval cancers,6 a somewhat different categorisation 
was used compared to that of the current study, which makes it difficult to 
judge whether the recent technical improvements have influenced at all the 
distribution among the various categories. This distribution not only depends 
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on the categories actually used but also on the definition of the (fairly subjec-
tive) cutoff point for a positive test result. If an aggressive screening strategy 
is applied (i.e., emphasis is laid on the detection of as many cancers as poss-
ible) then some "minimal sign present" cases will be classified as "screening 
errors". If the differences in classification are taken into account, the results of 
the patients with interval cancer in the current study agree fairly well with 
those published in these papers (Tables 3.1, 3.2).3"6 
Table 3.5 Result of eight successive screening rounds m the Nijmegen programme 
Round No of Positive Screen- Cancer Speci- Interval Interval % 
women test detected detection ficity cancer' cancer interval 
screened result cancer* rate' rate" rate* cancer* 
(%) 
19,702 
19,787 
16,629 
15,091 
16,169 
16,478 
16,464 
15,184 
254 
198 
122 
125 
110 
81 
98 
82 
75 
77 
49 
45 
56 
61 
57 
54 
3 81 
3 89 
2 95 
3 11 
3 46 
3 82 
3 46 
3 75 
99 09 
99 39 
99 56 
99 47 
99 66 
99 88 
99 75 
99 81 
31 
36 
32 
35 
26 
37 
41 
14« 
1 57 
1 82 
192 
2 32 
1.61 
2.24 
2 49 
— 
29 
32 
35 
43 
32 
37 
42 
— 
" Lobular carcinoma in situ not included 
f
 Per 1000 women screened 
* Relative to screen-detected + interval cancers 
s
 Follow-up period not yet completed 
No reports are available on screen-detected cases for comparison with our 
results. In almost 10% of these cases, the diagnosis was delayed by 2 years 
because of a false-negative screening result. Furthermore, the percentage of 
"minimal sign present" cases (48%) was striking. Only 43% of the screen-
detected cases did not show any radiologic signs at all on their previous 
mammogram (Table 3.2). 
A reduction of the screening interval from 2 years to 1 year may reduce the 
number of interval cancers and advance the time of detection of some of the 
screen-detected cases. All "screening error" cases without clinically suspect 
signs in the interscreening period probably would be discovered at the next 
screening, 1 year later. Thus, in our population the diagnosis would have been 
made 1 to 7 months earlier in six out of the seven interval cancers, and 1 year 
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earlier in the four screen-detected cancers. In addition, some cases in the 
categories "minimal sign present" and "radiographically occult" at the previous 
screening may have shown clear malignant signs 1 year later. In the patients 
with interval cancer, however, 55% of the "minimal sign present" cases and 
25% of the "radiographically occult" cases were diagnosed clinically within a 
year, so annual screening would not have been of any benefit to them. It is not 
clear if advancing the diagnosis with a maximum of 1 year would have any 
effect in further reducing the breast cancer mortality. 
Obviously, screening errors should be prevented as much as possible. This 
can be achieved in various ways —for example by thorough training of the 
radiologists and mammography radiographers, by ensuring a high technical 
quality of the mammography films and by applying double reading.12 
It may be wondered whether not at least a proportion of the "minimal sign 
present" cases might have been detected at the previous screening round. If 
less specific signs had been accepted for a positive test result, the increase in 
false-positive results would have been considerably greater than the increase in 
true-positive ones. This is illustrated by Moskowitz in a study of 40,431 
mammographie screening examinations.13 If "benign appearing masses" had 
been included in the definition of a positive screening result, the number of 
false-positives would have increased by approximately 600, whereas 6 addi-
tional cancers (true-positive results) would have been detected. 
Insight into the magnitude of the increase in sensitivity and the decrease in 
specificity might be obtained by studying the prevalence of minimal signs on 
the screening mammograms, and relating the outcome to the diagnosis. A 
radiological analysis of these cancers is necessary to find out whether these 
signs can be specified in such a way that the sensitivity is improved without 
any significant decrease in the specificity of the mammographie screening test. 
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One versus two-view mammography in baseline 
screening for breast cancer: a review 
JAAM van Dijck, ALM Verbeek, JHCL Hendriks, R Holland 
Abstract 
Two-view mammography is generally preferred as an initial screening 
examination because the number of missed carcinomas and false positive 
results in one-view mammography is considered to be large. The present 
review was performed to assess the difference in screening quality between 
one- and two-view mammography. Nineteen previous studies were 
reviewed and differences in sensitivity as well as specificity of two-view 
and one-view mammography were calculated. The results ranged from 
- 5.7% to 19.4% (median 3.9%), and 2.7% to 36.1% (median 14.8%), 
respectively, and indicate a higher screening quality of two-view 
mammography. However, in the studies considered there is a large vari-
ation in study population, screening tests used and assessment of disease 
outcome, which makes the numerical results less conclusive. None of the 
studies provided adequate information for deciding whether two-view 
mammography in baseline screening for breast cancer is preferable to one-
view mammography. If a screening programme using one-view 
mammography has already achieved high sensitivity and specificity, the 
value of an additional craniocaudal view is only marginal. 
Introduction 
The maximum reduction in breast cancer mortality that can be reached by 
mammographie screening depends to a large extent on the quality of the 
screening test. Ideally all women with preclinical breast cancer should show 
positive, and all others negative, screening test results. 
Since the introduction of mammography in breast cancer screening, the 
number of views to be used, particularly for the first screening examination, 
has been debated. Two-view mammography, i.e. mediolateral oblique and 
craniocaudal projections of each breast, has been criticized because compared 
with one-view, i.e. the oblique projection, the radiation dose is twice as high, 
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the costs are higher, and it takes longer to perform and interpret. However, 
sensitivity and specificity may both decrease if only one view is used. 
In theory, if two independent screening tests instead of one are med, more 
cases of the disease will be detected (higher sensitivity), and more women 
without the disease will have a false positive test result (lower specificity) 
because the combined result is positive if both tests are positive as well as if 
either one of the tests is positive.14 The test result of a two-view mammogram, 
however, is not the same as the combined result of an oblique and craniocau-
dal projection read separately because further evaluation of the lesion on the 
second view may lead to a negative two-view result. This means that the 
sensitivity of two-view mammography is not necessarily higher and the speci-
ficity is not necessarily lower than that of one-view. 
Different studies on this subject have reached different conclusions. Some 
authors recommend one-view mammography because only very few cancers 
would be missed.1517 Others argue that in one-view mammography the number 
of false negative results or the number of false positive results is too high,18'23 
especially in women with dense breast tissue.24·25 The extensive and expensive 
diagnostic tests which will follow a false positive screening result may cause 
severe strain or physical harm to women and will lead to extra costs. 
The best way to evaluate the screening quality of one-view versus two-view 
mammography would be to conduct a randomized controlled trial. Random 
allocation of the target population, i.e. women who are having a baseline 
screening for breast cancer, to one or two-view mammography would ensure 
comparability of populations in terms of prevalence and spectrum of malignant 
and benign breast disease as well as breast parenchyma. Only one screening 
centre and one radiologist should be involved, to avoid variation in technical 
quality of the mammograms and between observers. Follow-up for a year 
should allow for clinical diagnosis of those with false negative results. 
The population of such a study would have to be very large to be able to 
estimate the sensitivities and specificities with acceptable precision because 
breast cancer is a relatively rare disease (at initial screening about seven breast 
cancer cases may be detected in 1000 women screened). Before deciding 
whether or not such a large-scale randomized study is justified, the difference 
in sensitivity and specificity between two-view and one-view mammography 
was quantified in the present literature review, with special emphasis on 
design and study population. 
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Studies and methods 
Identification and selection of published studies 
A list of published studies was compiled by checking literature references and 
by performing a MEDLINE CD-ROM search covering the period up to July 
1991. The index terms used were "breast neoplasms" and "mammography", 
followed by a search for "view(s)" and "projection(s)" in title and abstract. 
Studies could only be included if the test results had been related to the 
diagnosis and if the numbers of true and false positive results and true and 
false negative results of both mammographie tests had been presented. 
Nineteen studies were included. All the studies were reviewed for the methods 
of sampling the study population, the mammographie tests compared, and the 
proper assessment of disease outcome of the study population (particularly 
women with a negative screening test result). 
Test characteristics of two against one-view mammography 
If the tests are evaluated in the same population, the respective numbers of 
women with and without the disease are equal for the two and one-view situ-
ations: A+C = a+c and B+D = b+d (Table 3.6). 
Test results reported in more than two alternatives, for instance "negative", 
"additional views required" and "positive" or "negative", "probably malig-
nant" and "malignant", were made dichotomous by regarding "negative" as the 
negative test result, and all other alternatives as positive. 
The percentage difference in sensitivity between two- and one-view 
mammography, Dsais, was calculated as the difference in true positive results 
divided by the number of breast cancer patients, multiplied by 100 (see Equa-
tion (1), Table 3.6). The percentage difference in specificity between the two-
and one-view test, Dspec, was calculated as the difference in true negative 
results divided by the number of "non-cases", multiplied by 100 (see Equation 
(2), Table 3.6). 
The reciprocal of the number of cases [1/(A+C)] and the reciprocal of the 
number of non-cases [1/(B+D)] were defined as indicators of the precision of 
D ^ and Dspec, respectively, and were calculated. If in any study two or more 
radiologists had read both the one- and two-view mammograms, a combined 
difference in sensitivity and specificity was calculated, using the mean differ-
ence in true positives and true negatives, respectively. 
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Table 3.6 Sensitivity and specificity of two-view and one-view screening test 
Two-view mammography One-view mammography 
Breast cancer 
yes no 
Breast cancer 
yes no 
Test result 
A 
С 
В 
D 
Test result 
a 
с 
b 
d 
A+C B+D a+c b+d 
Sensitivity = 
Specificity = 
A+C 
D 
B+D 
A-
'
α
χ 1 0 0 % = A-
Sensitivity = 
Specificity = 
"
f l
xl00% 
a 
a + c 
d 
b+d 
A+C 
D-d 
B+D 
a+c 
x
 100% =-5-^x100% 
b+d 
A™·' Difference in sensitivity between two-view and one-view mammography. 
D^: Difference in specificity between two-view and one view mammography. 
Results 
Eighteen publications were selected. Buchanan & Jager26 described 2 
substudies, both of which were included; Muir and colleages21 reported 3 
substudies of which only the first one could be used, so that in all, we 
included a total of 19 studies. Table 3.7 summarizes the studies according to 
population size, age, and modifiers of ϋ
Μ 1 Β and D s p e c. These modifiers include 
population characteristics, such as screening or patient population, tests 
applied and assessment of disease outcome, on which the sensitivity and speci­
ficity are dependent. By implication, DM n s and Dspcc will depend on these 
factors as well. A more detailed description of these modifiers is given in the 
Discussion section, below. 
All studies can be criticized with regard to at least one modifier. The studies 
listed in the upper part of Table 3.7 report on populations or compare tests 
that are inadequate to answer the question posed by this review. 
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Table 3 7 Studies according to population size, age and modifiers ofD
sens
 and Д 
Study No No of Age Population Tests applied Out 
of "non- (yrs) come" 
cases cases" A B C D E F G H I 
Weishaar 1976" 
Locker 1988" 
Moskowitz 197718 
Andersson 1978" 
Bassen 198327 
Muir 198421 
Bassett 19872* 
Bassett 198925 
Cukier 197724 
Buchanan 197726 1st 
Buchanan 1977м 2nd 
Huppe 1977я 
Libshitz 197630 
Pagani 198031 
223 
352 
31 
478 
80 
0 
169 
169 
106 
160 
50 
277 
88 
53 
0 
0 
119 
0 
0 
303 
194 
0 
0 
0 
30 
0 
0 
20 
nm 
nm 
nm 
nm 
33-87 
45 64 
28-94 
nm 
nm 
nm 
nm 
nm 
nm 
nm 
+ — 
- -
± -
± -
± -
— — 
— 
+ 
-
+ 
-
nr 
+ 
+ 
-
-
+ 
-
+ 
+ 
nr 
nr 
-
nr 
nr 
+ 
— 
nr 
nr 
nr 
nr 
nr 
nr 
nr 
-
+ 
-
+ 
+ 
+ 
+ 
+ 
-
-
-
+ 
— 
+ 
+ 
— 
+ 
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
-
± 
-
± 
± 
+ 
+ 
± 
+ 
-
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
-
-
+ 
+ 
nr 
nr 
± 
nr 
nr 
-
+ 
nr 
nr 
nr 
+ 
nr 
nr 
+ 
Lundgren 197615 
Andersson 198120 
Sickles 198622 
Anttinen 198932 
Ikeda 198823 
34 
117 
27 
34 
5 
860 
100 
2473 
269 
995 
35 + 
45-69 
nm 
50-52 
av57 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
— -
- -
+ + 
— + 
nr + 
— 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
— 
± 
-
+ 
_ 
+ = yes, — = no, ± = partly, nm not mentioned, nr not relevant (in column D and J 
because no non-cases were included, in column С because D
saa
 was not calculated), av 
average 
A asymptomatic population (breast cancer screening programme), В baseline screening, 
С cases include those with initially false negative results, D non-cases randomly sampled 
from initially true negatives and false positives E cc+oblique versus oblique (if — 
lateral view or three-view), F film-mammography (if — xero), G revision of both tests 
(if ± two-view results by combining separately read oblique and cramocaudal views), H 
revision without additional information, I no use of "additional views 
requested/equivocal " 
' Diagnostic work-up/follow-up of the screening test negatives (if ± women with false 
positive one-view result were free of breast cancer) 
NOTE Bassett 198?" and Bassett 198923 based on the same patients and including the 80 
patients of Bassett 198327 
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Table 3.8 Sensitivity of two-view mammography, D^, two-view specificity and Dq>cc 
according to study 
Study 
Weishaar 197616 
Locker 198817 
Moskowitz 197718 
Andersson 1978" 
Bassett 198327 
Muir 198421 
Bassett 198728 
Bassett 198923 
Cukier 197724 
Buchanan 197726 1st 
Buchanan 197726 2nd 
Hüppe 1977м 
Libshitz 1976м 
Pagani 198031 * 
Lundgren 197615 
Andersson 198120 
Sickles 198622 
Anttinen 198932 
Ikeda 198825 * 
Sensitivity 
2-view 
100%* 
81.8% 
100%* 
94.3% 
100% 
— 
84% 
91.9% 
99.1% 
100%* 
96.0%* 
96.4% 
96.6%* 
81.6% 
100% 
100%* 
100% 
87.5% 
— 
D O T ' 
1.3% (0.004) 
3.9% (0.003) 
19.4% (0.032) 
4.7 (0.002) 
1.3% (0.013) 
— 
- 5 . 7 % (0.006) 
6.4% (0.006) 
1.4% (0.009) 
1.3% (0.006) 
-2 .0% (0.020) 
8.7% (0.004) 
3.4% (0.0011) 
8.5% (0.019) 
0% (0.029) 
6.3% (0.009) 
7.4% (0.037) 
18.4 (0.029) 
— 
Speci­
ficity 
2-view 
— 
— 
100%* 
— 
— 
95.7% 
87.7% 
— 
— 
— 
90.0%* 
— 
— 
— 
93.8% 
97.4%* 
93.9% 
66.9% 
98.8% 
I V 
— 
— 
36.1% (0.008) 
— 
— 
5.3% (0.003) 
26.3% (0.005) 
— 
— 
— 
21.0(0.033) 
— 
— 
— 
14.8% (0.001) 
4.4% (0.010) 
18.8% (0.0004) 
2.7% (0.004) 
4.9% (0.001) 
" In parentheses: precision ofD
slns (1/(A + C): see text) and D^ (1/(B+D): see text) 
* Based on original screening or diagnostic test result 
* D not calculated because no test results of the non-cases were given by the author 
D
se
n not calculated because of small number of cases 
Table 3.8 shows sensitivity and specificity of two-view mammography, as 
well as D
sens
 and D
spec. Dsens was calculated from 17 studies and ranged from -
5.7% to 19.4% (median 3.9%, mean 5.0%, standard deviation 6.5%). D
spec 
was calculated from nine studies and varied from 2.7% to 36.1% (median 
14.8%, mean 14.9%, standard deviation 11.6%). 
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Figure 3.1 shows Dsens (vertical axis) in relation to the precision (horizontal 
axis). In 14 out of 17 studies the sensitivity of two-view was higher than that 
of one-view (Dsens>0%), while one study showed no difference. In two 
studies Dsaa was very high (18.4% and 19.4%), but these studies lacked 
precision. In the studies listed in the lower part of Table 3.8 DMI1S does not 
seem to differ from the values for the studies in the upper part, although 
tending to be less precise. 
Figure 3.2 shows Dspec (vertical axis) against precision (horizontal axis). The 
variation is very large. In 4 studies D ^ varies from 2.5% to 5.5%, but in 5 
other studies it varies from 14.8% to 36.1%. Dspec tends to be larger and less 
precise for the studies listed in the upper part of Tables 3.7 and 3.8. 
Figure 3.3 shows Dsens and Dspe. simultaneously for those studies that report 
both sensitivity and specificity (only 7 studies do so). No relation between 
Dsen5 and Dspec can be observed. 
Figure 3.1 Dsens (%) and corresponding precision in 17 studies 
Dsens (%) 
15-
10-
• * 
5 · 
• · 
0 * 
-5 -
0 0,01 0.02 0,03 0,04 
Precision (1/(A+C): see text) 
• Studies listed In •*· Studies listed In 
the upper part of the lower part of 
Tables 3.7 and 3.8 Tables 3.7 and 3.8 
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Figure 3.2 D (%) and corresponding precision in 9 studies 
D*pac(K) 
0,005 0,01 0,015 0,02 0,025 
Precision (1/(B*D) see text) 
• Studies Ilated In * Studies Usted In 
the upper part of the lower part of 
ТаЫеа 3 7 end 3.8 Tables 3 7 and 3 8 
0,03 0,04 
Figure 3.3 D
stnl(%) and D. m 7 studies reporting both sensitivity and specificity 
D»P«(*) 
Usted in Ine upper 
pert of Tables 3 7 
and36 
5 
Dsara(S) 
• Usted In the lower 
part of Tables 3 7 
and 3 8 
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Discussion 
The sensitivity and specificity of a screening test are influenced by charac-
teristics of the study population, the test applied, and the assessment of disease 
outcome. As a consequence, Dstns and Dspec may also be affected by these 
modifiers. Table 3.7 presents the studies according to numbers of breast 
cancer cases and "non-cases", age (which was rarely mentioned), and presence 
(+) or absence (-) of several items on which the modifiers were scored. 
First, study populations should be samples from the general population and 
not taken from a clinic where women present with breast complaints. The 
larger tumor size at diagnosis yields higher sensitivities and the presence of 
benign breast disease yields lower specificities, which increases the likelihood 
of differences in DSM1S and Dspec. Furthermore, cases as well as controls should 
be included. In populations of breast cancer cases only the sensitivity cannot 
be assessed properly because visibility of the tumor on one projection will 
almost certainly lead to a positive test result if the radiologist is aware of the 
diagnosis of breast cancer for the whole set of cases. Also, case series should 
include women with false negative mammographie screening results, whereas 
control series should be a random sample of all "non-cases" (those with 
initially true negative or false positive results). In populations of only women 
with initially (true or false) positive test results some kind of lesion will be 
present on all mammograms, which will make it very difficult to decide which 
are negative. Even if a large sample of screen-negatives are included the 
results will be biased, as can be illustrated by Lundgren and Jakobsson's 
study.15 Here 210 women with positive one-view screening results, 65 women 
with a positive history and 618 of 5804 with negative screening results had 
three-view mammography. One and three-view mammograms were reviewed 
by a blinded radiologist. In this study population, specificities were 79.5% and 
94.3%, respectively, but in the unselected screening population, one-view 
specificity was as high as 97.0%. In conclusion, unbiased estimates of DspŒ 
can only be obtained if the "non-cases" are a random sample of those with 
initially true negative or false positive screening results. 
The technical quality of the mammograms and the reading ability of the 
reviewing radiologists vary between the studies. Interobserver variation can be 
illustrated by Anttinen's study in which four radiologists read the same 
mammograms.32 Radiologist l's reading of one-view mammograms had a 
higher sensitivity than radiologist 4's reading of two-view. However, Radi-
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ologist l's specificity on two-view reading was much lower than that of Radi-
ologist 4 on one-view reading. 
Furthermore, the use of xerography, three-view mammography, the lateral 
view, or the availability of previous mammograms will influence the study 
result. Moreover, if in any study only the oblique view is reviewed and the 
results are compared with the screening results of two-view mammography, 
work-up bias and inter-observer variation can occur. Finally, in some studies 
one of the alternative qualifications was "additional views required for con-
firmation of malignancy" or "equivocal". It will be clear that many more ver-
dicts of "additional views required" are found at one-view readings. If the 
radiologist must choose between "positive" and "negative" without the option 
of "additional views", they will sometimes choose "negative", which leads to 
different cut-off points for a positive test for one- and two-view 
mammography. 
A final modifier of Dsens and Dspec is the assesment of disease outcome. The 
definitive diagnosis (presence of absence of breast cancer), which is required 
for the calculation of sensitivity and specificity, will be known for women 
whose screening yielded positive results who then underwent diagnostic tests. 
Those whose test results were negative, on the other hand, are not tested 
further; and some may be falsely negative because not all breast cancers show 
mammographically suspect signs at the screening examination.6 Dspec will 
hardly change because the number of true negatives is usually large and con-
stant. Therefore, follow-up data must be available to provide information on 
the number of cancers missed at the screening but diagnosed clinically later 
on, allowing for an unbiased estimation of Dsens. 
Tables 3.7 and 3.8 show two groups of studies. Those in the upper part of 
the Tables reported on the population and/or applied tests which were not very 
suitable in answering the question of this review. The median Dsens of the 
studies of the lower part of Table 3.8 was 6.9%. The negative sign for Dsens 
and the very large DspK in Bassett's28 and Buchanan's26 studies have probably 
been caused by the use of the alternative score "additional views required". In 
Lundgren and Jakobsson's study15 Dsens might have been larger than zero if 
follow-up data had been available to adjust for cancers missed at one-view 
screening but detectable at two-view. 
According to Figure 3.2, all nine studies had fewer false positive results 
with two-view mammography. Dspa: was largest in studies listed in the upper 
part of Table 3.8. Considering only studies listed in the lower part of Table 
3.8, the median for Dspec was 4.9%. Assuming Dspw = 5% and a two-view 
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specificity of 90%, then of 10,000 women screened 1,000 will have a false 
positive result on two-view mammography and 1,500 on one-view 
mammography. If the two-view specificity is 99%, then these numbers are 
100 and 600, respectively. In both examples the difference is 500 false posi-
tive results, but in the first, one-view yields 50% more false positive results 
and in the second 500%. 
It can be concluded that two-view mammography detects more cases and 
reduces the number of unnecessary diagnostic tests. However, the differences 
can hardly be assessed. Probably the gain in sensitivity and specificity by the 
addition of the craniocaudal view is highest for radiologists who are relatively 
inexperienced in reading mammograms. They may not be able to reach a high 
sensitivity as well as a high specificity even with two views available. 
Whether the two-view screening test is more effective depends not only on 
Dsens and Dspec, but also on the sensitivities and specificities themselves. For 
example, Peeters and colleagues reported a sensitivity of 93% and a specificity 
of 99% of a screening test consisting of one-view mammography only.7 If 
with the oblique view alone 93% of the breast cancer cases can be detected 
and only 1% of the women without breast cancer must undergo unnecessary 
diagnostic tests, it may be concluded that although two-view may yield more 
true positive and true negative results, it will probably be less cost-effective. If 
the baseline mammograms are read by less experienced radiologists, the speci-
ficity of one-view mammography may be too low, and then two-view may be 
more cost-effective. 
Acknowledgements 
We thank F. de Groot for his comments. 
Validity of mammography - Discussion 53 
Discussion 
Age-specific detectability 
In the detectability study, the previous mammogram was studied for tumour 
characteristics and breast parenchyma. This section makes a secondary 
analysis of the detectability study, in order to examine the association with age 
at the screening examination reviewed. Table 3.9 shows the classification of 
84 previous mammograms according to age at invitation to the previous 
screening. In the interval cancer patients, the results for the age categories 55-
64 and 65-79 years are comparable, whereas in the younger age category, the 
proportion of "radiographically occult at previous screening" is larger and the 
proportion of "minimal signs present" is smaller than in the older age cat-
egories, although the numbers are too small to reach statistical significance. 
Probably, these minimal signs are more difficult to detect in younger women 
with denser breasts. Furthermore, the growth rate of breast cancer in younger 
women may be faster and thereby the preclinically detectable phase of the 
tumour may be shorter.33 In patients with screen-detected cancers, there were 
no differences in the classification of the previous mammogram according to 
age. 
Table 3.9 Classification of previous screening mammograms of 84 breast cancer 
patients, according to age when the previous mammogram was taken 
Cancer and 
age category 
Interval cancer 
42-54 yrs 
55-64 yrs 
65-79 yrs 
Screen-detected 
cancer 
42-54 yrs 
55-64 yrs 
65-79 yrs 
No. of 
cases 
40 
14 
19 
7 
44 
12 
11 
21 
Classification of previous mammogram in % 
Screening 
error 
18% 
14% 
21% 
14% 
9% 
8% 
9% 
10% 
Minimal 
sign 
28% 
14% 
37% 
29% 
48% 
50% 
45% 
48% 
Radio-
graphically 
occult 
42% 
50% 
37% 
43% 
43% 
42% 
45% 
43% 
Radiographi-
cally occult 
at diagnosis 
12% 
21% 
5% 
14% 
n.a. 
n.a. 
n.a. 
n.a. 
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The publication of our detectability study in Cancer encouraged researchers in 
the Florence programme to review the previous screening mammograms of 
134 patients using the same design and criteria.34 The previous mammograms 
were classified as 16% "screening error", 27% "minimal sign present", 54% 
"radiographically occult" and 7% "radiographically occult at diagnosis" (com­
pared to 13%, 38%, 43% and 6% in the Nijmegen study, respectively). The 
differences in the proportion classified as "minimal signs" and "radiographi­
cally occult" show that the classification is subjective even when the same cat­
egories are used. Explanations for this are variation in the visual observation 
and perception and in the threshold of concern about perceived abnormal­
ities.35 In a retrospective review of 73 "negative" mammograms in patients 
who later developed breast cancer, the classification of 3 radiologists showed 
disagreement in as many as 19% of the cases.36 
The most common reason for screening errors is related to perception error. 
Of the 11 screening errors in the detectability study, 8 had not been perceived 
by the radiologists, despite the fact that these mammograms had been double 
read. Recent research is focussing on computer-assisted reading of 
mammograms. It may be possible to develop software that can detect lesions 
that a radiologist would overlook, but it will not be able to interprete the 
lesions. Computerized pre-screening in the function of one of the double 
readers may be helpful to detect and mark visible lesions in large series of 
screening mammograms, so that the radiologist as the second reader can 
concentrate on his interpretation. 
One versus two-view mammography: an update of the review 
The hypothesis in our review that the sensitivity and specificity of two-view 
mammography for initial screening would be higher than one-view 
mammography, could not be quantified because of the poor study designs. 
Recently, several well-designed studies have been published. Thurfjell and 
colleagues37 conducted a study on 12,636 women aged 40-54 years who 
underwent two-view mammography in their initial screening round. One 
radiologist examined the single oblique view and later on in the day both 
views. The recall rates for one- and two-view mammography were 4.3°/00 and 
2.8°/00, the biopsy rates were 4.δ
0/«, and 5.Tl
w
 and the number of cancers 
detected were 31 and 32, respectively. None of the differences were statistical­
ly significant. 
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In London, a study was carried out on 26,430 women aged 50-64 years who 
had been screened with two-view mammography.38 One of the views and the 
two-view mammograms were read independently by the same radiologist and 
resulted in recall rates of 9.1% and 6.7% (McNemar's test P<0.001) and 
detection rates of 7.8°/«, to 8.3%,, (McNemar's test Ρ<0.01), respectively. The 
reduction in the cost due to the decreased recall rate was not sufficiently large 
to neutralize the extra cost of the second view. 
Wald and associates39 reported on a large randomized controlled trial that 
was set up to study the difference in screening results between one-view and 
two-view mammography. A total of 40,163 women aged 50-64 years at their 
first screening were recruited from 9 English screening centres. At each 
centre, the women were assigned at random to one of three groups in the ratio 
1:1:2. Group 1 were screened with one-view and groups 2 and 3 with two-
view mammography. The oblique view of groups 1 and 3 were read by reader 
X, whereas the two views in groups 2 and 3 were read by reader Y, inde­
pendently from X. Every month X and Y switched groups. Twenty-one 
readers took part, 19 of them were radiologists. In groups 1 and 2, the recall 
rates were 8.2 and 7.0 per 100 women screened, the biopsy rates were 7.5 
and 7.4 per 1000 women screened and the detection rates were 5.6 and 6.5 
per 1000 women screened, respectively. In group 3, in which 115 cancers 
were detected, the results for one-view and two-view mammography were 
recall rates of 8.5% and 6.3%, biopsy rates of 7.5°/00 and 7.4°/00 and detection 
rates of S^/oo and 6.8°/oo, respectively. In group 3, 24 of the 115 cancers had 
been detected by only 1 method: 23 by two-view and 1 by one-view 
(McNemar's test: Ρ < 0.0001). The cost of two-view screening was higher, but 
the average cost per cancer detected was about equal. The authors concluded 
that two-view screening is more effective and has similar cost-effectiveness. 
These studies support the opinion that a cranio-caudal view should be per­
formed in addition to the oblique view for initial screening. The gain in sensi­
tivity and specificity seems to be much larger than anticipated. It must be 
stressed, however, that these results will depend on the specific programme. 
In the first round of the Dutch programme, the rate of referral for diagnostic 
work-up a hospital was much lower (1.3%)40 than in Wald's trial, which was 
situated in the UK programme, although in both the programmes two-view 
mammography was used. Probably, the increase in sensitivity of two-view 
mammography was the same in the Dutch programme but the decrease in the 
referral rates may have differed because of the lower referral rates with one-
view mammography. 
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The question remains as to whether two-view mammography is also prefer-
able for subsequent screening. Wald et al39 speculated that the decrease in 
recall rate (and thus specificity) at subsequent screening may be smaller than 
at initial screening and the interpretation of benign lesions would be facilitated 
by previous two-view mammography. The gain in sensitivity would be as 
large as it was at initial screening, because the detection of malignant lesions 
would not be affected by the previous mammogram. One could argue, 
however, that the identification of malignant lesions will also be facilitated by 
the availability of previous two-view mammography, so that the increase in 
sensitivity due to the cranio-caudal view would also be less. Future research 
could assess the gain in quality of two-view mammography over one-view for 
subsequent screening. 
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Mammographie screening after the age of 65 years: early 
outcomes in the Nijmegen programme 
JAAM van Dijck, ALM Verbeek, JHCL Hendriks, R Holland, M Mravunac 
Abstract 
We studied outcomes of mammographie screening in women older than 65 
years. In 1975, breast cancer screening was started in Nijmegen, the 
Netherlands, for women aged 35 to 65 years. Since 1977, approximately 
7700 older women have also been invited for biennial one-view 
mammography. This report is based on 10 screening rounds from 1975 to 
1994. The results of the subsequent screening rounds in the age groups 65-
69, 70-74 and 75 years and older were: participation rates 55V„ 39*/, and 
157,, screen-detected cancer rates 5.67«, 6.9*/. and 7.87., interval cancer 
rates 2.07,. 1.87,, and 3.57.., predictive values of referral 627., 647. and 
627,, respectively. In all age groups, screen-detected patients had smaller 
tumours and a lower prevalence of axillary lymph node involvement than 
unscreened patients. Our conclusion is that in women aged 65 years and 
older, breast cancer can be detected at an earlier stage by biennial 
mammographie screening. 
Introduction 
Breast cancer is the commonest malignancy in women. The incidence of 
invasive breast cancer in the Netherlands rises with age to about 340 new 
diagnoses annually per 100 000 women aged 70 years and older.1 Approxi-
mately one out of three new cases of invasive breast cancer is diagnosed in 
this age group. Although it has often been argued that this disease is more 
indolent in older women, their relative survival is no better than for younger 
women.2 
Several trials have been conducted and reviews of the results show that 
mammographie screening can reduce breast cancer mortality by approximately 
30%.35 Recently, it was shown that mammographie screening of women aged 
65-74 years can also reduce breast cancer mortality.6"8 
To evaluate screening programmes that may have differently aged target 
populations, background material is necessary in order to assess the early 
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results. For women aged 50-69 years, this information is available from sev-
eral regional and national programmes,9"12 but for the older age groups, the 
information is limited. 
The aim of the present study was to determine age-specific outcomes of 
mammographie screening, with emphasis on women aged 65 years and older, 
in the Nijmegen programme, which is the only long-running trial in the world 
that did include women over 75 years of age.13 
Study population and methods 
In 1975, a population-based screening programme for breast cancer was start-
ed in Nijmegen, The Netherlands. In 1975 and 1976, approximately 30000 
women aged 35-65 years received their first invitation to participate in the 
mass mammographie screening. From the second round onwards, some 7700 
older women were also invited for biennial one-view mammography. From 
1975-1994, ten screening rounds were carried out. Details of the programme 
and the round-specific results up to round 9 are published elsewhere.13 
The present analyses included primary breast cancer patients diagnosed 
before December 1994. Excluded were patients with lobular carcinoma in situ, 
patients diagnosed before their first invitation to screening, and women under 
the age of 50. Age, defined as the age on the date of invitation, was categor-
ised as 50-64, 65-69, 70-74 and 75 years and older. 
The following indicators were studied for first and subsequent invitations 
separately: participation rate (i.e. number of accepted invitations per 100 
invitations), referral rate (i.e. number of referrals for diagnostic work-up per 
1000 accepted invitations), screen-detected cancer rate (i.e. number of screen-
detected patients per 1000 accepted invitations), interval cancer rate (i.e. 
number of patients diagnosed clinically after a negative screening result but 
before the next scheduled invitation 2 years later per 1000 accepted invita-
tions) and non-participant cancer rate (i.e. number of cancers diagnosed clini-
cally in non-participants per 1000 rejected invitations). The predictive value of 
referral (i.e. the number of diagnosed breast cancer patients per 100 referred 
women) and the ratio of screen-detected patients to screen-detected plus inter-
val cancer patients were also calculated. Tumour size and lymph node status 
were studied according to the detection mode: (1) detected at first screening 
(including screen-detected patients who had rejected the invitation 2 years 
earlier), (2) detected at repeated screening (i.e. in women who had also par-
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ticipated in the previous round), (3) diagnosed clinically as an interval cancer 
and (4) diagnosed clinically in non-participants (i.e. in women who had 
rejected the most recent invitation). Tumour size was measured in millimetres 
(mm) as the largest measurable size on the mammogram, or on the specimen 
radiography and histological slides if the tumour had vague margins or was 
radiographically occult. Axillary lymph node status was studied in patients 
diagnosed after 31 December 1980. Before this date, axillary lymph node 
dissection was not performed as a routine procedure and, as a result, the 
lymph node status was missing in 34% of the patients. From 1981 onwards, 
the axillary lymph node status was missing in 10% of the patients. 
The statistical tests used were the Kruskall Wallis test to analyse differences 
in median tumour size and the chi-square-test for contingency tables to test 
differences in proportions. The analyses were performed with the statistical 
software package SAS. 
Results 
Table 4.1 shows the number of invitations and the participation rates, referral 
rates and cancer rates for the first invitation. The participation rates for the 
first invitation decreased dramatically at older ages from 81% in women aged 
50-64 years to 24% in women aged 75 years and older, while those for the 
subsequent invitations were some 10% lower at all ages. Table 4.2 shows 
corresponding details for subsequent invitations. The initial high rates of 
referral and detection (18% and 9%) dropped in the subsequent invitations to 
levels of about 10 and 6 per 1000 accepted invitations in women aged 65 years 
and older. The breast cancer detection rates in women who had been screened 
regularly (i.e. those also screened in the previous round) remained fairly high 
at 3.0, 5.5, 6.0 and 6.3 per 1000 accepted invitations for the four age groups, 
respectively (not included in the tables). Interval cancer rates were slightly 
higher after subsequent invitations than after the first invitation. The non-
participant cancer rates did not increase in the older age groups. The predic-
tive value of referral was very high. At subsequent invitations, breast cancer 
was diagnosed in two out of three referred women aged 65 and older. The 
ratio of screen-detected cancers to the sum of screen-detected plus interval 
cancers was 0.69 or higher in women older than age 65. 
Table 4.3 shows the tumour size of invasive cancers, categorised as < 10 
mm, 11-20 mm and >20 mm, according to the detection mode and age. The 
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Table 4.1 First invitations: screening results according to age at invitation 
Screening result 
No. of invited womei 
No. of participants 
Participation rate (%) 
Referrals 
Screen-det. cancers 
Interval cancers 
Non-particip. cancers 
I 
No. 
Rate1 
No. 
Rate* 
No. 
Rate' 
No. 
Rate" 
Predictive value of referral (%) 
Ratio screen-detected to 
screen-detected+interval 
50-64 
13149 
10591 
81 
158 
14.9 
604 
5.7 
17' 
1.6 
14' 
5.5 
38 
0.78 
Age at invitation 
65-69 
2328 
1440 
62 
22 
15.3 
81 
5.6 
21 
1.4 
3 
3.4 
36 
0.80 
70-74 
3122 
1450 
46 
27 
18.6 
152 
10.3 
3 
2.1 
5 
3.0 
56 
0.83 
(years) 
75 + 
4253 
1009 
24 
20 
19.8 
13' 
12.9 
2 
2.0 
13 
4.0 
65 
0.87 
Total 
22852 
14490 
63 
227 
15.7 
96s 
6.6 
242 
1.7 
35' 
4.2 
42 
0.80 
Superscript denotes number of duaal carcinoma in situ included 
" per ¡000 accepted invitations 
* per 1000 rejected invitations 
median tumour sizes (with 25th and 75th centiles) are also presented. In each 
age group, the median size was smallest in the cancers detected at repeat 
screening and largest in non-participant cases (P values < 0.001). The pro-
portion of large tumours detected at first screening or those diagnosed in non-
participants was somewhat larger in the oldest age groups (chi-square=5.62, 
d.f. = 3, P=0.13; chi-square=5.82, d.f.=3, P=0.12), while the proportion of 
large interval cancers was slightly smaller in the oldest women (chi-
square=5.17, d.f.=3, P=0.16). 
Table 4.4 shows the lymph node status of women diagnosed between 1981 
and 1994. Overall, the percentage 'unknown' was 5%, 6%, 5% and 30% in 
the four age groups, respectively (chi-square=92.4, d.f. =3, P<0.001). 
Breast cancer specific survival was poorest in patients with an unknown lymph 
64 Chapter 4 
node status; the 10 year breast cancer specific survival rate was 0.40 for 
patients with unknown lymph node status, whereas it was 0.61 for patients 
with positive nodes and 0.92 for patients with negative nodes. This illustrates 
the importance of considering all diagnosed patients instead of only those with 
a known lymph node status as the denominator for the proportion of patients 
with negative nodes. The proportion of lymph node negative patients differed 
according to the detection mode (chi-square=65.8, d.f.=3, P<0.001). In the 
patients detected at repeat screening it was 74% while in non-participants it 
was 41%. In non-participants aged 75 years and older, the proportion of 
lymph node negatives was smaller than in the younger non-participants (34% 
and 47%, respectively, P=0.03). 
Table 4.2 Subsequent invitations: screening results according to age at invitation 
Screening result 
No. of invitations 
No. of participations 
Participation rate (%) 
Referrals 
Screen-det. cancers 
Interval cancers 
Non-particip. cancers 
Predictive value of 
(*) 
Ratio screen-detected 
No 
Rate' 
No. 
Rate' 
No. 
Rate" 
No. 
Rate" 
referral 
to 
screen-detected+interval 
50-64 
98851 
66073 
67 
401 
6.1 
2204' 
3.3 
132s 
2.0 
1073 
3.3 
55 
0.63 
Age 
65-69 
28398 
15708 
55 
143 
9.1 
88" 
5.6 
322 
2.0 
512 
4.0 
62 
0.73 
at invitation 
70-74 
21079 
8116 
39 
87 
10.7 
56' 
6.9 
15 
1.8 
492 
3.8 
64 
0.79 
(years) 
75 + 
33949 
5129 
15 
65 
12.7 
40s 
7.8 
18' 
3.5 
1223 
4.2 
62 
0.69 
Total 
182277 
95026 
52 
696 
7.3 
40460 
4.3 
197' 
2.1 
329'° 
3.8 
58 
0.67 
Superscript denotes number of ductal carcinoma in situ included 
' per 1000 accepted invitations 
b
 per 1000 rejected invitations 
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Table 4.3 Tumour size of invasive cancers according to detection mode and age at 
invitation 
Detection mode and 
tumour size 
Age at invitation (years) 
50-64 
Detected at first screening' 
¿10 mm 
11-20 mm 
>20 mm 
Total 
Median (25-75 cenale) 
25 (28) 
46 (51) 
19 (21) 
90 
15 (10-20) 
Detected at repeat screening 
<10 mm 
10-20 mm 
>20 mm 
Total 
Median (25-75 cenale) 
Diagnosed as interval 
¿10 mm ¿10 mm 
10-20 mm 
>20mm 
Total 
Median (25-75 cenale) 
57 (39) 
66 (46) 
22 (13) 
145 
15 (10-18) 
cancer 
19 (14) 
65(46) 
56 (40) 
1402 
20 (15-30) 
Diagnosed in non-participants 
<10 mm< 10 mm 
10-20 mml 1-20 
> 2 0 m m > 2 0 mm 
TotalTotal 
Median (25-75 cenale) 
12(11) 
30 (28) 
66 (61) 
108' 
25 (19-35) 
65-69 
5(29) 
10 (59) 
2(12) 
17 
15 (10-15) 
27 (38) 
35 (49) 
9(13) 
71' 
15 (10-20) 
3(10) 
14 (45) 
14 (45) 
31 
20 (15-30) 
4 ( 8) 
13 (27) 
32 (65) 
49' 
26 (20-35) 
70-74 
4(16) 
16(64) 
5(20) 
25 
20 (15-20) 
14 (38) 
21 (55) 
2 ( 6 ) 
371 
15 (10-18) 
4(24) 
11 (65) 
2(12) 
17' 
15 (15-20) 
2 ( 4) 
18 (35) 
31 (61) 
51' 
25 (15-35) 
75 + 
5(21) 
9(38) 
10 (41) 
24 
20 (14-27) 
11 (48) 
7(30) 
5(22) 
23 
12 ( 7-20) 
4(24) 
8(47) 
5(29) 
172 
20 (13-25) 
5 ( 4 ) 
27 (23) 
88 (73) 
12012 
30 (20-40) 
Total 
39 (25) 
81 (52) 
36 (23) 
156 
15 (11-20) 
109 (40) 
129 (47) 
39 (14) 
2762 
15 (10-20) 
30 (15) 
98 (48) 
77 (38) 
205s 
20 (15-30) 
23 ( 7) 
88 (27) 
217 (66) 
328B 
30 (20-35) 
Percentage between parenthesis 
Superscript indicates the number of missing values 
' Includes screen-detected patients who had rejected the previous screen invitation 
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Table 4.4 Axillary lymph node status of women diagnosed after 1980 according to 
detection mode and age at most recent invitation 
Detection mode and Age at invitation (years) Total 
lymph nodes 
50-64 65-69 70-74 75 + 
Detected at first screening* 
Negative0 22 (61) 
Positive 13 (36) 
Not examined 1 ( 3 ) 
Total 36 
Detected at repeat screening 
Negative" 107 (78) 
Positive 27 (20) 
Not examined 3 ( 2 ) 
Total 137 
Diagnosed as interrai cancer 
Negative" 69 (63) 
Positive 34(31) 
Not examined 6 ( 6 ) 
Total 109 
Diagnosed in non-participants 
Negative" 44 (46) 
Positive 45 (47) 
Not examined 7 ( 7 ) 
Total 96 
7(70) 
3(30) 
0(0) 
10 
44(69) 
19 (30) 
1(2) 
64 
19(66) 
10 (34) 
0(0) 
29 
20 (48) 
15 (36) 
7(17) 
42 
13 (76) 
3(18) 
1(6) 
17 
30 (77) 
9(23) 
0(0) 
39 
7(50) 
3(21) 
4(29) 
14 
21 (47) 
23 (51) 
1(2) 
45 
6(55) 
3(27) 
2(18) 
11 
14(64) 
4(18) 
4(18) 
22 
12 (67) 
4 (22) 
2(11) 
18 
41 (34) 
36 (30) 
43 (36) 
120 
48 (65) 
22 (30) 
4(5) 
74 
195 (74) 
59 (23) 
8(3) 
262 
107 (63) 
51 (30) 
12(7) 
170 
126 (42) 
119 (39) 
58 (19) 
303 
* Includes screen-detected patients who had rejected the previous screen invitation 
b
 women with DCIS included as negative 
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Discussion 
Mammographie screening can obviously only reduce the mortality of breast 
cancer in the population if at least a part of the invitees participates. The 
participation rates in women for the first invitation (65-69 years, 81%; 70-74 
years, 67% and 51% for older women), declined for subsequent invitations 
(64% for ages 50-69, 39% for ages 70-74, and 15% for older women). These 
rates were very disappointing compared to the two-county trial in Sweden, in 
which, among women aged 70-74 years, 72% participated after subsequent 
invitations.14 
The effect of screening in the women who actually do participate may 
appear fairly large because the women who continue to participate have a 
longer life-expectancy. In another study, we found a marked difference in 
survival of women who continued to participate at the age of 65-66 years 
compared to those who discontinued. The 10 year cumulative survival rates 
were 0.87 and 0.73, respectively.7 In Stockholm, similar results were reported 
in participants and non-participants aged 40-64 years.15 It is possible that 
participants had fewer co-existing diseases or they were less severe. There 
may even be an interaction between breast cancer and certain co-existing dis-
eases. In breast cancer patients with localised or regional disease, Satariano 
and Ragland16 found that the probability of survival decreased with an increas-
ing number of co-existing conditions, whereas in patients with distant 
metastases, the 3 year survival rate did not depend on the number of other 
conditions. They concluded that women with severe co-existing diseases would 
not have a survival advantage because of early diagnosis. 
One of the reasons for participation may be awareness of the presence of 
risk factors for breast cancer. If this is true, non-participants will be at less 
risk of breast cancer. The finding that the non-participant cancer rates did not 
increase with increasing age, in contrast with the screen-detected cancer rates 
and interval cancer rates, supports this hypothesis. In women over the age of 
65, these non-participant cancer rates were approximately 2 per 1000 rejected 
invitations per annum, whereas the annual incidence of breast cancer in the 
Netherlands is about 3.5 per 1000 women.1 In another study, we also observed 
that the incidence of breast cancer in the non-participants was lower than 
would have been expected on the basis of a population without mass screen-
ing.7 This means that one explanation for the high incidence in elderly partici-
pants, which was 4.5 per 1000 accepted subsequent invitations per annum at 
ages 65+ (calculated by the summation of screen-detected cancer and interval 
68 Chapter 4 
cancer rates in Table Π) may be that the women who participate at a more 
advanced age are at greater risk for breast cancer. However, part of the 
increased incidence in participants may be artificial, because some of the 
detected cancers may never have become clinically detectable. 
As the breast cancer incidence increases with increasing age, it was 
expected that screen-detected cancer rates and interval cancer rates would also 
show the same pattern. Owing to the slower growth rate17 it was expected that 
the ratio of screen-detected to screen-detected plus interval cancers would 
increase with increasing age. In the 75+ group, however, the proportion of 
interval cancers was relatively high. In order to find an explanation for this 
result we reviewed the previous screening mammograms of 17 out of the 18 
interval cancers. Two tumours (12%) had been missed at the previous screen­
ing examination; five tumours (29%) were visible in retrospect, but the signs 
were not specific enough for referral; and ten tumours (59%) had been radio-
graphically occult at the previous screening. These findings are in agreement 
with the results of our study in 1993 and do not provide an explanation for the 
high interval cancer rate.18 
Two indicators of stage, i.e. tumour size and lymph node status, were 
studied. In all age groups, screen-detected tumours were the smallest. 
Tumours detected at repeat screening had a median size of roughly 15 mm, 
whereas in non-participants the median size was 25 to 30 mm. In all age 
groups there was a similar increase in the proportion of patients with negative 
axillary nodes due to detection at repeat screening VÍ clinical detection in non-
participants. Thus, it may be concluded that, through periodic screening with 
mammography in women over the age of 65, breast cancer can be detected at 
a similar early stage as in those aged 50-64 years. 
In summary, our data show that, in women aged 65 years and older, breast 
cancer can be diagnosed at an earlier stage by mammographie screening. This 
does not imply that the life-expectancy of all screen-detected patients will be 
longer. First, a larger proportion of the screen-detected cancers may have 
remained undiagnosed without screening because of the slow growth rate.17 
Second, women of 75 have a life expectancy of 11 years and those of 85 of 6 
years.19 The duration of the detectable preclinical phase in women aged 70 
years and older has been estimated at 4.5 years.20 It is thus unlikely that many 
breast cancer deaths can be prevented in patients screened at age 75 years and 
older, but the quality of life may be increased if screening can prevent them 
from having to live for years with metastases. 
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We conclude that there is reason to continue mammographie screening until 
at least the age of 75 years. The beneficial effects of mammographie screening 
on breast cancer mortality and the quality of life may outweigh the negative 
side-effects until the age when life expectancy is shorter than the detectable 
preclinical phase of the disease. 
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Introduction 
Assessment of the effect of mammographie screening on breast cancer mortal-
ity is most straight forward in randomized controlled trials. Comparability of 
the population with regard to underlying breast cancer mortality is guaranteed 
by the random assignment of the study population to an invitation group and a 
non-invitation group and analysing the results according to the randomization 
groups. Usually, the ratio is calculated between the risk of dying from breast 
cancer in the invited group and the risk in the non-invited group. 
The Nijmegen screening project, however, was not set up as a randomized 
study. All the female inhabitants of Nijmegen aged 35 years and older were 
invited for screening. A useful method to perform effect measurements in such 
a non-randomized study is the case-referent approach. The ratio can be calcu-
lated between the breast cancer mortality rates of screened versus unscreened 
women. Using such a design, the study population consists of all the patients 
who were invited for screening and died from breast cancer in the study 
period (the cases), and a sample of all invited women (the referents). All the 
study subjects are classified according to participation in the screening. Next, 
the ratio of the "quasi-rates" is calculated as the number of screened cases to 
the number of screened population referents divided by the number of 
unscreened cases to the number of unscreened population referents. Although 
the absolute mortality rates for screened and unscreened women remain 
unknown (the true denominators, which consist of the number of woman-years 
of observation in each group, are unknown), this ratio of "quasi-rates" is a 
valid estimator of the ratio of the true mortality rates. 
This Chapter contains two such case-referent studies which have been pub-
lished in The Journal of the National Cancer Institute 1994; 86: 934-8 and The 
International Journal of Cancer 1996; 66: 727-31, respectively. The difference 
between these studies with regard to the definition of the relevant screening 
histories is outlined in the Discussion section of this Chapter (page 93). Fur-
thermore, bias due to self-selection is discussed, which forms a major limita-
tion in case-referent studies to assess the reduction in mortality due to screen-
ing. 
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Efficacy of mammographie screening of the elderly: a case-
referent study in the Nijmegen programme in The Netherlands 
JAAM van Dijck, R Holland, ALM Verbeek, JHCL Hendriks, M Mravunac 
Abstract 
Only a few small studies have been conducted to examine the usefulness of 
mammographie screening in elderly women. These studies suggest that the 
screening-related reduction in breast cancer mortality rates is less than the 
estimated 20-40% reduction observed for women aged 50-70 years at the 
time of their first screening. We have studied the efficacy of continued 
mammographie screening for breast cancer of elderly women within our 
screening programme. 
In 1975, a breast cancer screening programme was started in the city of 
Nijmegen, The Netherlands. During each biennial screening round, 
approximately 30 000 women aged 40 years and older were personally 
invited to participate. Single-view mammography was administered. The 
present study was conducted using a case-referent design. In order to be 
eligible for inclusion in this study, women had to have been invited to 
participate in the mammography screening programme at least twice, with 
the most recent invitation having occurred when each woman was 65 years 
or older. The cases studied comprised 33 women in this group who had 
died of breast cancer at some point during 1977 through 1988. Referents 
were matched for age at last invitation to screening prior to the diagnosis 
of breast cancer and for the number of previous invitations to screenings. 
Five referents were randomly selected for each case. Breast cancer mortal-
ity rate ratios (RR) were calculated for several categories of attendance to 
the screening. 
The RR of those who attended the last screening versus those who failed 
to do so was 0.58 (95% confidence interval [CI] = 0.24-1.41); for women 
aged 65-74, the RR was 0.34 (95% CI = 0.12-0.97) and for women aged 
75 or over, 2.87 (95% CI = 0.62-13.2). The RR of those who attended the 
screening before and after the age of 65 relative to those who attended 
before 65 only, was 0.26 (95% CI = 0.05-1.32). 
Although self-selection bias was present in our data, it was not likely to 
be responsible for the beneficial effect in women aged 65-74 at the time of 
invitation to screenings. It probably was responsible for the reversed RR 
(RR > 1) in the group of women 75 years and older. Continuation of 
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mammographie screening until at least the age of 75 years may lead to a 
reduction of breast cancer mortality among elderly women. 
Introduction 
Mammographie screening for breast cancer is at present the most effective 
method in reducing breast cancer mortality. In various reviews of published 
studies it was concluded that breast cancer mortality may be reduced by ap-
proximately 20-40% in women aged 50-70 years at time of entry into the 
screening programme, whereas for women under 50 years of age, no reduc-
tion was evident.13 Currently, it is a matter of considerable debate whether the 
elderly should be screened. Most studies on the effect of mammographie 
screening have focused on women younger than 70 years at entry.4"10 The few 
studies that did report on the elderly are indicative of an effect of mammo-
graphie screening somewhat smaller than that in the younger age group, with 
the degree of reduction in breast cancer mortality being in the range of 15 to 
20%.1114 However, several questions remain unanswered, such as if continu-
ation of screening after the age of 70 has the potential to reduce mortality, and 
whether or not an upper age limit should be set.15 
In the Netherlands, mammographie screening for breast cancer is now being 
introduced nationwide.16 Women aged 50-69 years are personally invited every 
2 years. Women aged 70 years and older are not invited because evidence of a 
reduction in breast cancer mortality for this group is still lacking. The lack of 
evidence for benefit from such screening, however, does not imply that a 
beneficial effect does not, in fact, exist. On the other hand, there will be a 
certain age above which the number of women who die of causes other than 
breast cancer before the date at which breast cancer would have been diag-
nosed without screening inevitably becomes unacceptably high. 
The most important issue, i.e. whether or not screening should be continued 
in the elderly, has never been studied. Therefore, we decided to investigate 
the efficacy of screening women aged 65 years and older for breast cancer 
using a population that had already been included in the mammographie 
screening programme previously. The two most important differences between 
the present study and earlier studies were the following: 1) The subjects 
should have had at least two invitations to the screening before the diagnosis 
of breast cancer, and 2) age was defined as "age at invitation to the screening 
examination under study" instead of "age at entry in the screening programme". 
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Study population and methods 
Study setting 
In 1975, a breast cancer screening programme was started in the city of 
Nijmegen, the Netherlands. Biennially, single view mammography was admin-
istered. Single view mammography consisted of the latero-medial view in 
rounds 1 to 3, and the medio-lateral oblique view thereafter. At every screen-
ing round, approximately 30,000 women aged 40 and over were personally 
invited to participate. Details of the programme have been previously pub-
lished.17 In Table 5.1 the attendance rates of round 7 (1987-88), which can be 
regarded as representative of a steady state period regarding attendance rates, 
are presented. With increasing age, a strong decline in attendance was evident, 
whereas for those women who had already participated in round 6, attendance 
was much higher. 
Table 5.1 Attendance rates of round 7 of the Nijmegen breast cancer screening pro-
gramme (separately for all invited women and participants in round 6) by age 
at invitation 
Age at 
invitation 
round 7, y 
40-49 
50-64 
65-69 
70-74 
75-79 
> 80 
Total 
No. 
invited 
7,634 
10,908 
3,382 
2,995 
2,482 
2,756 
30,157 
All invited women 
No. 
screened 
5,359 
7,227 
1,815 
1,282 
594 
187 
16,464 
Attendance 
rate, % 
70,2 
66,3 
53,7 
42,8 
23,9 
6,8 
54,6 
Already participated in 
No. 
invited 
4,546 
7,092 
1,841 
1,356 
699 
251 
15,785 
No. 
screened 
3,973 
6,387 
1,569 
1,057 
477 
130 
13,593 
round 6 
Atte 
rate 
ndanc 
87.4 
90.1 
85.2 
77.9 
68.2 
51.8 
86.1 
Study design and population 
The present study was designed as a case-referent study, with the odds ratio 
(OR) as the estimator of the ratio of the breast cancer mortality rates (rate 
ratio, [RR]) of women who had accepted the invitation to the screening rela-
tive to those who had not.18 Because our aim was to examine the effect of a 
continuation of the screening in the elderly, only those women were included 
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in the study who had been invited to participate at least twice, most recently at 
the age of 65 years or over. 
Case patients were defined as women who had died of breast cancer before 
1989. The cause of death, classified by a panel of physicians, was based on 
the clinical course of the disease as well as on the death certificates. Breast 
cancer was defined as the cause of death if the following evidence existed: 1) 
the disease had progressed to distant sites, 2) this progression was ultimately 
responsible for the death of the patient, and 3) other causes of death could be 
excluded. Using this set of criteria, we identified 33 cases. 
Referents were individually matched with each case patient for age at last 
invitation to participate before the diagnosis and for the number of previous 
invitations to screenings. Using the following criteria, we selected a set of 
eligible referents to match each case19 (a) alive and residing in Nijmegen at the 
time of death of the case patient, (b) free of breast cancer at the invitation to 
the last screening before the diagnosis of breast cancer in the case patient, (c) 
having the same age as the case patient at the invitation to the last screening 
before the diagnosis, and (d) having been invited to the same screening rounds 
as the case patients before the diagnosis. Five referents were selected random-
ly from each set, resulting in 165 referents. 
Data analysis 
We calculated breast cancer mortality RRs with 95% confidence intervals 
(CIs) by maximum likelihood estimation through conditional logistic regression 
analysis13·14 with the statistical package EGRET (Statistics and Epidemiology 
Research Corporation, Seattle, Wash.). First, we calculated the RR of those 
who had attended the screening after the last invitation before the diagnosis of 
breast cancer the case patient relative to those who had failed to attend. (This 
was the same screening round for a case patient and her 5 referents). In this 
analysis the indicator for screening was "1" if the subject had undergone 
mammographie screening after the last invitation and "0" if the subject had not 
undergone screening in response to the last invitation to participate. 
Next, the mammographie screening history of each woman was divided into 
four categories of participation: 1) participation before the age of 65 only, 2) 
participation before and after the age of 65, 3) participation after the age of 65 
only, and 4) no participation at all. Because of our interest in the effect of a 
continuation of the screening, category 1 (participation before 65 only) was 
chosen as the reference category. Indicators for the three other categories of 
participation were included in the regression model. This latter model was also 
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analyzed for indicators of participation before and/or after the ages of 70 and 
75 years, respectively, in order to estimate the effect of a continuation of the 
screening above these age limits as well. 
Self-selection bias 
Self-selection bias is a major problem in case-referent studies on intended 
effects, because the reasons for participation may be associated with the out-
come. The extent of a possible bias was studied by calculating the ratio of 
observed and expected breast cancer deaths in the nonparticipating population 
over a 10-year period. A ratio of 1 suggests absence of bias, whereas a ratio 
smaller than 1 indicates that the real effect is underestimated (RR closer to 1) 
or reversed (RR > 1). 
The population of the neighbouring city of Arnhem was used as the refer-
ence population because in the period of 1970-1974, it had the same age-
adjusted incidence and mortality rates of breast cancer as those in Nijmegen,15 
and because no mass screening programme had ever been implemented in 
Arnhem. Since 1975, data on Arnhem patients diagnosed as having primary 
breast cancer have been carefully recorded by the Carcinoma Werkgroep 
Arnhem. The cause of death was ascertained using the same criteria described 
for the case patients. The age-specific mortality rates of breast cancer in this 
reference population in the period 1978 to 1988 (deaths were counted only if 
breast cancer had been diagnosed after the start of the screening in Nijmegen) 
were applied to the woman-years of observation of the nonparticipants (i.e., 
the time between the refused first invitation to screening up to the first attend-
ance, up to relocation from Nijmegen, up to death, or up to the end date, 
December 31, 1988). Thus, the expected numbers of breast cancer deaths in 
Nijmegen were calculated. The standardized mortality ratio is defined by the 
ratio of observed and expected numbers of breast cancer death.23 
We also used this procedure to calculate the standardized morbidity ratio; 
however, the numbers of primary breast cancer cases were assessed instead of 
breast cancer deaths for the years from 1977 to 1988. 
Results 
Table 5.2 shows the attendance of the 33 case-referent sets after the last invi-
tation to the screening as well as the RR. The numbers refer to the number of 
case-referent sets. For example in the age category 65-74, there were no sets 
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with the case and zero, one, four, or five out of five referents screened just 
before diagnosis of the case, one set with the case and two out of five refer­
ents screened, and four sets with the case and three out of five referents 
screened. The overall RR was 0.58 (95% CI 0.24-1.41). For women aged 65-
74 years at invitation to screening, the RR was 0.34 (95% CI 0.12-0.97), and 
for women aged 75 years or more, the RR was 2.87 (95% CI 0.62-13.2). 
Table 5.2 Case-referent sets according to attendance at the screening after the last 
invitation before diagnosis and RR (95% CI) according to age at invitation 
Age at Case No. of referents who Total No. RR+ (95% CI) 
invitation, attended attended* of cases 
years 
65-74 
S75 
Total 
Yes 
No 
Yes 
No 
Yes 
No 
0 
0 
2 
2 
5 
2 
7 
1 
0 
2 
1 
3 
1 
5 
2 
1 
3 
0 
1 
1 
4 
3 
4 
7 
0 
0 
4 
7 
4 
0 
2 
0 
0 
0 
2 
5 
0 
0 
0 
0 
0 
0 
5 
16 
3 
9 
8 
25 
0.34(0.12-0.97) 
2.87 (0.62-13.2) 
0.58 (0.24-1.41) 
" Cell entries denote the number of sets of one case and five referents, arranged according 
to attendance to the last screening. For example, in the age-category 65-74 years in the 
fourth column, there are four sets with the case and three out of five referents screened 
just before the diagnosis of the case. 
+ Breast cancer mortality rate ratio, calculated by maximum likelihood estimation. 
Table 5.3 displays some model specifications, the numbers of cases in each 
category and the results of the analysis of a continuation of the screening after 
age 65. The RR of participants before and after age 65 relative to participants 
before age 65 only, was 0.26 (95% CI 0.05-1.32). Participation before and 
after age 70 relative to participation before age 70 only, resulted in a RR of 
0.38 (95% CI 0.03-4.15), and for participation before and after age 75 versus 
before age 75 years only, it was 8.92 (95% CI 0.86-92.1). 
Table 5.4 shows the age-specific mortality rates in Arnhem, the observed 
(O) and expected (E) numbers of breast cancer deaths in the Nijmegen nonpar-
ticipants, and the ratio of О to E. The O/E ratio was larger than 1 in the 
younger age categories and smaller than 1 in the highest age categories [test 
for heterogeneity of ratios:17 chi square = 16.9, d.f. = 3, Ρ = 0.001]. 
Because of this heterogeneity of ratios, no standardized mortality rate ratio 
was calculated. The very high O/E in the age category 70-74 is probably due 
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to the surprisingly low mortality rate in Arnhem. The most striking finding in 
Table 5.4 is the very low ratio of observed and expected deaths in women 80 
years and older, although the observed numbers of deaths in Nijmegen were 
very small. 
Table 5.3 Model specifications and results of the conditional logistic regression analysis 
of the continuation of the screening after age 65 
Indica­
tor 
χ. 
x 2 
Хз 
Index category" 
participation before and 
after 65 (n = 3) 
" participation after 65 only 
(n = 8) 
no participation at all 
(n = 18) 
Definition 
X, = 1 if yes 
X, = 0 if no 
X2 = 1 if yes 
X2 = 0 if no 
X3 = 1 if yes 
X3 = 0 if no 
Results 
b+ 
-1.33+ 
-0.21 
0.59 
SE(b) 
0.82 
1.05 
0.93 
P-value 
0.11 
0.84 
0.53 
The number of cases in each category are shown in parentheses. 
' Reference category: participation before 65 only (n=4) 
+ b = estimated parameter of exposure category X¡ in the logistic regression model 
+
 RR = 0.26 (95% Cl 0.05-1.32). Participation before and after age 70 versus before 
age 70 only, RR = 0.38 (95% CI = 0.03-4.15). Participation before and after age 75 
versus before age 75 only, RR = 8.92 (95% CI = 0.80-92.1) 
Table 5.4 Age-specific breast cancer mortality of reference population in Arnhem: 
observed and expected numbers of breast cancer deaths in the Nijmegen 
nonparticipants by age in the period 1978-1987 
Age at 
death, 
years 
65-69 
70-74 
75-79 
>80 
Total 
Population of Arnhem 
No. of 
breast 
cancer 
deaths' 
24 
12 
18 
37 
91 
Woman 
years 
33,321 
29,439 
22,460 
23,547 
108,767 
Mortality 
rate 
xlO3 WY 
72.0 
40.8 
80.1 
157.1 
83.7 
Nijmegen nonparticipants 
Woman 
years at 
risk+ 
4,893 
7,753 
9,509 
13,293 
35,448 
Breast 
deaths 
Obs. 
(О) 
4 
7 
7 
6 
24 
cancer 
Exp. 
(E) 
3.5 
3.2 
7.6 
20.9 
35.3 
O/E 
1.14 
2.18 
0.92 
0.29 
0.68+ 
* Only if diagnosed after the start of the screening in Nijmegen. 
+ Adjusted for deaths, removals, and participation to the next invitation. 
+ Test for heterogeneity of ratios24: chi square = 16.9; d.f = 3, Ρ = 0.001 
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The observed number of cases of primary breast cancer was lower than 
expected in all strata of age (range of ratios, 0.54-0.89; test for heterogeneity 
of ratios: chi square = 3.95, d.f. = 3, ρ > 0.10). The standardized morbid­
ity ratio was 0.68 (95% CI 0.53-0.88). 
Discussion 
Several studies showed a beneficial effect of screening in the elderly, but no 
single result proved to be statistically significant.11"14 In an earlier study of the 
Nijmegen programme, based on 16 cases and 80 age-matched referents of age 
65 and over at first invitation to screening, an OR of 0.81 (95% CI 0.23-2.75) 
was found after 7 years of follow-up.11 
In a two county trial conducted in Sweden, an RR of 0.77 was reported 
after 8 years of follow-up (95% CI 0.47-1.27) in the age category 70-74 at 
entry.12 A recent update of this trial with 13 years of follow-up showed an RR 
of only 0.94 (95% CI 0.60-1.46) in the same population but with the end point 
"breast cancer present at death" in stead of "death due to breast cancer". 
In the Breast Cancer Detection Demonstration Project (BCDDP), another 
study including elderly women, the RR was analysed by means of a compari­
son with population-based data from the Surveillance, Epidemiology and End 
Results Program,* and a value of nearly 25% (no confidence bounds provided) 
was calculated for the ages 60-74 at entry.13 
Another study was published based on data from the Duke Tumor Regis­
try.14 This study included 109 case subjects who were 60 years and older at 
diagnosis and who had developed metastatic breast cancer as well as 211 
controls who had been selected by random sampling from the same tumor 
registry. Only 6% of the controls had ever been screened. The OR, adjusted 
for several risk factors, was 0.73 (95% CI 0.25-2.14). 
All of these studies showed some beneficial effects of mammographie scree­
ning in the elderly, but none of them addressed the effect of a continuation of 
mammographie screening. The screening history was divided into the cat­
egories of "ever" screened and "never" screened in the former Nijmegen11·22 
and Duke Tumor Registry studies.14 Women who had been previously 
screened, however, may have failed to participate in the more recent 
screenings, and these were the screenings that should have caused the reduc­
tion in mortality. The Swedish studies compared the RR of the invited popula­
tions with that of the uninvited populations.12·25 The differences in attendance 
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rates between women aged 70-74 years at entry in the study and those aged 
60-69 years (79% and 91%, respectively) may largely explain the differences 
in the estimated effects after 8 years (RR = 0.77 and 0.65, respectively).2 
Moreover, age was defined in all of these studies as age at entry in the pro-
gramme or at diagnosis, in spite of the fact that the actual age at screening 
may be quite different. In addition, three of the studies included self-selected 
populations,11·13·14 but they failed to control for this selection in the analysis. 
However, the extent of the self-selection bias was studied in the Nijmegen11 
and BCDDP13 studies. In these two studies, it was argued that the calculated 
effect must have been smaller than the real effect because of the self-selection 
bias. 
Finally, misclassification of the end-point may have played an important 
role in all of these studies. With increasing age, the increase in co-morbidity 
frustrates the determination of the cause of death and increases in the chance 
of a misclassification, thus resulting in a RR closer to 1. In addition, once 
breast cancer has been diagnosed, death may be attributed to the disease. This 
may lead to an overreporting of death due to breast cancer in the screened 
population, in contrast to death in the unscreened population, and thus may 
result in a RR closer to 1. 
It is likely that the overview of the Swedish trials may have suffered from 
misclassification because the end point "breast cancer present at death" was 
used.25 That study reported that the RR calculated on this end-point was simi-
lar to that calculated on the end-point "breast cancer as primary cause of 
death", 0.77 and 0.78, respectively. These RRs were calculated in the whole 
study population in the age group 40-74 years. There may, however, have 
been a substantial difference for the elderly. As pointed out above, more 
breast cancer cases are bound to be diagnosed in the invited group, thus more 
women may die "with breast cancer present", resulting in an underestimation 
of the RR. 
In the present study, participation in the screening just before diagnosis 
resulted in a reduction of the breast cancer mortality rate of 42%, although 
this result was not very precise. In the categories encompassing 65-74, the 
effect was greater (66%) and more precise. Also, the effect of a continuation 
of the screening on the breast cancer mortality was calculated. It was not 
possible to compare different screening strategies (i.e. screening until the age-
limit versus continuation of screening), because all women had been invited 
and had decided themselves whether or not to continue participation. The 
results are suggestive of a beneficial effect of the continuation of the screening 
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both after the age of 65 (RR = 0.26, 95% CI 0.05-1.32), and after the age of 
70 (RR = 0.38, 95% CI 0.03-4.15). However, after the age of 75 the effect 
is reversed (RR = 8.92, 95% CI 0.86-92.1). 
Besides the misclassification of the cause of death, self-selection bias could 
be an explanation for the RR greater than 1 found in the oldest age group. 
Attendance rates decreased strongly with increasing age, even in women who 
had attended the previous round (Table 5.1). Attendance may be associated 
with an increased risk (e.g. as a result of the presence of a palpable mass or 
other symptoms), which would explain a higher underlying incidence and 
mortality rate in the screened group. The incidence rates in the nonparticipants 
aged 65 or older as well as the mortality rates in the nonparticipants aged 75 
or older were lower than expected on the basis of the data from Arnhem 
(Table 5.4). Although the number of observed deaths was larger than expected 
in the age group 65-74, this has little meaning for the interpretation of our 
study because of the difference in the definition of age (age at death, whereas 
the analyses were done according to age at time of invitation). Assuming that 
the incidence and mortality rates in Nijmegen and Arnhem were identical in 
the absence of screening, the underlying incidence and mortality rates in the 
participants of the same ages must be higher. Because of this self-selection 
bias, the effect will be diluted or even reversed, i.e. a beneficial effect in 
women aged 75 years or older may not be excluded, although unlikely. 
Incidence and mortality rates of breast cancer continue to rise with increas-
ing age and about 30% of invasive breast cancer is diagnosed in women aged 
70 and over.26·27 In this age group the likelihood of being diagnosed with meta-
static disease is highest28 and the relative survival is worst.26·27 As the tumor 
growth rate decreases,29 the lead time will be longer and the disease may be 
diagnosed even earlier because of screening. Thus, a greater effect of the 
screening may be expected, although this is more difficult to assess because of 
the complications in determining the cause of death. Breast cancer detection by 
mammography is enhanced,30 and interval cancer rates are lower in older 
women than in younger women.17 On the other hand, the extent of overdia-
gnosis may increase because more women with breast cancer will die in the 
lead time period from causes other than breast cancer. Even then, however, 
early detection may improve the quality of life, because less women will be 
diagnosed with metastatic disease.30 
Unfortunately, the present study, is not helpful in determining the upper 
age-limit for mammographie screening. It, however, indicates that continued 
screening of women up to the age of 75 might be beneficial. It is important to 
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note that, because of the self-selection bias and the increased likelihood of 
misclassification of the cause of death of women aged 75 and older, a benefi-
cial effect of mammographie screening for these women cannot be excluded. 
We conclude that a continuation of the mammographie screening until the age 
of 75 may reduce breast cancer mortality. 
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Mammographie screening after the age of 65 years: 
evidence for a reduction in breast cancer mortality 
JAAM van Dijck, ALM Verbeek, LVAM Beex, JHCL Hendriks, 
R Holland, M Mravunac, H Straatman, JM Werre 
Abstract 
We evaluated whether regular mammographie screening of women aged 
65 years or older affected breast cancer mortality. 
In Nijmegen, a population-based screening programme for breast cancer 
was started in 1975, with biennial mammography for women aged 35-64 
years. Since 1977, elderly women have also been participating. For the 
present case-control study, women were selected who were over 64 years 
of age at the most recent invitation. Eighty-two of them had died from 
breast cancer. For these cases, 410 age-matched population controls were 
selected. 
The ratio of breast cancer mortality rates of the women who had par-
ticipated regularly (i.e., in the 2 most recent screening rounds prior to 
diagnosis) vs. the women who had not participated in the screening was 
0.56 (95% CI = 0.28-1.13). The rate ratio was 0.45 in the women aged 
65-74 years at the most recent invitation (95% CI = 0.20-1.02), whereas it 
was 1.05 in the women aged 75 years and older (95% CI = 0.27-4.14). 
While the breast cancer survival rate of the non-participant patients was 
fairly equal to that of patients from a control population, the underlying 
incidence rate of breast cancer was higher in the participants than in the 
non-participants. Therefore, we conclude that bias was present, but that it 
had decreased our effect estimate. The real reduction in breast cancer 
mortality due to regular screening will be even larger. Regular mammo-
graphie screening of women over age 65 (at least up to 75 years) can 
reduce breast cancer mortality by approximately 45%. 
Introduction 
In women, the life time risk of developing breast cancer has been estimated at 
8.4 to 9.4%.31 For women aged 65-69 years the probability of developing 
breast cancer before the age of 85 years is 1 in 16 and for those aged 70-74 
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years 1 in 20.32 Thus even in the very elderly, many cases of breast cancer are 
diagnosed. The proportion of patients who die from this disease is as large as 
it is in younger women.33 In patients aged 65-84 years, 5-year relative survival 
rates vary from about 90% for those with localized disease, to 66-69% for 
those with regional disease and to 17-20% for those with distant disease.2* 
In the past few decades, several randomized and non-randomized trials have 
been undertaken to evaluate the effect of mammographie screening on breast 
cancer mortality. Extensive evaluations on the available evidence have led to 
the conclusion that a 30 to 40% reduction in breast cancer mortality can be 
achieved by periodic screening of women aged 50 to 65 or 70 years.13·25·34'35 
In women over the age of 70 years, evidence for a possible reduction in breast 
cancer mortality due to screening is lacking, because most trials did not 
include elderly women.34·36 
In the late eighties and the early nineties, national screening programmes 
were initiated in several European countries, such as the UK, the Netherlands 
and Sweden.37 The lack of data showing that screening was of benefit to 
elderly women was the principal argument for not inviting women aged 65 
years and more to screening programmes in the UK38 and for excluding 
women aged 70 years and older from programmes in the Netherlands.39 Nev-
ertheless, the question still remains as to whether continuing to screen women 
after they have reached these upper age limits will further reduce beast cancer 
mortality. With 18 years of follow-up data available in our Nijmegen screen-
ing programme from the first screening round up to 31 December 1993, we 
elected to conduct a case-control study on the effect of long-term participation 
after the age of 65 years on breast cancer mortality. 
Study population and methods 
Study setting 
In the city of Nijmegen, population-based screening for breast cancer has been 
ongoing since 1975. Biennially, nearly 30,000 women aged 40 years and older 
are personally invited to have a one-view mammogram. From round 2 (1977-
1978) onwards, about 10,000 women aged 65 years and older have also been 
invited to participate. At each screening round, individual data on invitation 
and participation are stored in a computer file. Another file is kept on all 
Nijmegen breast cancer patients diagnosed within and outside the programme. 
The follow-up of the population is registered with the help of the local author-
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¡ties, who provide weekly lists of deceased women and those who have moved 
out of Nijmegen. Details of the programme have been reported previously.40·41 
Study design and population 
Within the Nijmegen population of invited women, we conducted a case-con-
trol study in order to investigate the effect of regular participation in the 
screening programme from age 65 years onwards on breast cancer mortality. 
The study population consisted of women who (1) had been invited to partici-
pate at the age of 65 years or older and (2) had been free of breast cancer at 
the first screening invitation at age 65 years or older. 
The cases were the patients who had died of breast cancer before January 1, 
1994. The cause of death was classified by a panel of physicians who were 
unaware of the screening history of the patients and was based on the clinical 
course of the disease and information about serious co-morbidity. Breast 
cancer was defined as the cause of death if the disease had progressed to 
distant sites and this progression was ultimately responsible for the death of 
the patient, or if in the presence of advanced disease other causes of death 
could be excluded. Patients with advanced breast cancer who died of other, 
unrelated causes were not included as cases. The study population comprised 
82 cases. The screening round in which the case had received the most recent 
invitation just before the diagnosis of primary breast cancer was defined as the 
index round. For screen-detected cases the round in which the cancer had been 
detected was the index round. 
For each case, a group of eligible population controls were selected who (1) 
were alive and residing in Nijmegen at the time of death of the case, (2) had 
been invited to participate in the index round of the case, (3) were free of 
breast cancer at their index invitation, (4) were of the same age as the case at 
the index invitation. At random, 5 controls were selected for each case. Thus, 
the total number of controls was 410. 
Definition of contrasted screening histories 
A history of no screening was defined as no participation in the 5 most recent 
screening rounds up to and including the index round. Women in this category 
represented the reference category. A history of regular screening was defined 
as participation in the index round and having had a negative screening exam-
ination one round (approximately 2 years) earlier. Histories that did not meet 
the criteria for "no screening" or "regular screening", were classified as 
otherwise and formed a category we took no interest in. Cases and controls 
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were classified according to these categories of screening histories. 
Statistical analysis 
We calculated the odds ratio with its 95% confidence interval (95% CI) as an 
estimator of the ratio of breast cancer mortality rates (RR) in women with a 
history of regular screening versus those with a history of no screening.18 
Owing to the matched design, we used conditional logistic regression analysis 
with the software package EGRET. 
Results 
Age at the index invitation was identical for cases and their matched controls 
(range from 65 to 92 years). At the index invitation, 33% of the study popula-
tion were 65-69 years old, 24% were 70-74 years, 32% were 75-79 years and 
11 % were 80 years or older. 
The number of invitations was virtually the same for the cases and controls. 
Up to and including the index round, 23% of the cases and 21% of the con-
trols had been invited only once, 35% and 41% had been invited 2 to 4 times, 
respectively, whereas 41% and 39% had been invited 5-8 times, respectively. 
Table 5.5 Breast cancer mortality rate ratio for screening history according to age at 
index invitation 
Age at index 
invitation 
(years) 
All ages 
65-74 
75 and older 
Screening history 
no screening' 
regular screening2 
otherwise3 
no screening 
regular screening 
otherwise 
no screening 
regular screening 
otherwise 
Number of 
cases/controls 
40/166 
15/101 
27/143 
20/ 69 
12/ 87 
15/ 79 
20/ 97 
3/ 14 
12/ 64 
Breast cancer 
mortality rate ratio 
(95% CI) 
1 
0.56(0.28-1.13) 
0.77 (0.44-1.34) 
1 
0.45 (0.20-1.02) 
0.64 (0.30-1.38) 
1 
1.05(0.27-4.14) 
0.90 (0.40-2.02) 
' No participation in index round and 4 preceding rounds 
2
 Participation in index round and negative mammogram in preceding round 
3
 Not meeting the criteria for "unscreened" or "screened" 
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Table 5.5 shows the results of the conditional logistic regression analysis. 
The ratio of the breast cancer mortality rates (RR) of regularly screened 
women vs. unscreened women was 0.56 (95% CI = 0.28-1.13). In women 
aged 65-74 years at the index invitation the RR was 0.45 (95% CI = 0.20-
1.02); in the women aged 75 and older, the RR was 1.05 (95% CI = 0.27-
4.14). 
Discussion 
All over the world, the age-specific incidence of breast cancer is rising, 
especially among elderly women.42 At the time of diagnosis, elderly patients 
are more likely to have distant metastases or unknown stage disease than 
younger women.28,43 In the Nijmegen group of non-participants with ages 70 
years and older, 85% had stage II or stage 11+ cancer, in contrast with 77% 
of those aged 50-69 years. Among the regular participants, these percentages 
were 33 and 30, respectively.40 
After menopause, a large proportion of the fibroglandular breast tissue is 
replaced by fatty tissue, with greater radiological transparency,15 thereby 
facilitating the detection of breast cancer by mammography. In addition, the 
proportion of false-positive screening results will be lower because of the 
decreased frequency of benign breast disease. The growth rate of breast cancer 
is relatively low in elderly women. Peer et al.29 estimated that the median 
tumour volume doubling time is 80 days in patients younger than 50 years, 
157 days in patients aged 50-70 years and 188 days in older patients. The 
lower growth rate is in concordance with the higher rate of steroid-positive 
tumours.44 Life expectancy is relatively long, about 14 years at age 70 and 
about 8.5 years at age 80 years.45 For the reasons given above, an important 
reduction in breast cancer mortality can also be expected in elderly women 
due to mammographie screening. 
The few studies on the effect of breast cancer screening in women aged 65 
years and older are small and have methodological flaws. For instance, age 
specific analyses involve age at entry to the screening programme instead of 
age at screening and the comparisons are made between the "invited group" 
and the "control group" or between women "screened once" and those "never 
screened" ч.13·14·22·46.'" The most recent results from the Swedish 2 county trial 
for women aged 70-74 years at their first invitation for screening showed for 
the invited women a relative risk of 0.79 for death from breast cancer (95% 
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CI = 0.51-1.22), compared to the noninvited women.46 Analysis of the 
women aged 65-74 years at their first invitation revealed RR = 0.68 (95% CI 
= 0.51-0.89).47 In the Nijmegen programme, a case-control study was con-
ducted on women who had been invited at least twice.48 In this study, 33 cases 
and 165 controls aged 65 years and over at the index invitation were included. 
For women who had participated in the index screening, compared with those 
who had not participated, the RR was 0.58 (0.24-1.41). For women aged 65-
74 years at the index invitation, the RR was 0.34 (95% CI = 0.12-0.97); 
whereas in the older women, an excess of mortality was found which could be 
attributed to self-selection bias.48 In the present study, with 5 more years of 
follow-up and twice as many patients, the RR for women screened regularly 
compared with those not screened, was 0.56 (95% CI = 0.28-1.13); for 
women aged 65-74, the RR was 0.45 (95% CI = 0.20-1.02) and for women 
aged 75 or over, 1.05 (95% CI = 0.27-4.14). The agreement in the results, in 
spite of the difference in the definition of the relevant screening histories 
(participation in the index round for the former study and participation in both 
the index round and one round earlier in the present study), is noteworthy. 
Screening can only improve the prognosis of breast cancer if it can detect 
more breast cancer cases in a curable phase than can be diagnosed without 
screening. Maximum benefit can only be expected if a woman participates on 
a regular basis. In our study, the definition of a regular screening history 
applied to women who continued to participate up to and including the index 
round and had had a negative screening mammogram approximately 2 years 
earlier. This definition guaranteed that in regularly screened patients, breast 
cancer had been diagnosed as early as possible in the given screening pro-
gramme. Screening mammograms performed 2 or more rounds before the 
index invitation were not expected to have any influence on the diagnosis of 
breast cancer and were therefore not taken into consideration. The reference 
category with a history of no screening was also designed explicitly. After a 
negative screening result, a woman's risk of developing breast cancer is low 
initially, but it approaches that of unscreened women after several years. After 
about 10 years, preceding screening can be expected to have lost its effect. 
We therefore defined a history of no screening as being present if a woman 
had never participated at all, or if she had rejected the index invitation and the 
4 preceding ones. With this carefully designed contrast, we estimated that in 
women aged 65 years and older the reduction in breast cancer mortality for 
regularly screened women relative to the unscreened women was 44%. 
Non-randomized studies are liable to self-selection bias that may (in part) 
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explain the breast cancer mortality rate ratio observed in the screened vs. the 
unscreened group. Besides age, which was controlled for by matching, we 
only reviewed the information on previous referral for diagnostic work-up. 
Only 3 controls and no cases had been referred previously, so this cannot have 
caused any bias. However, there may have been a difference in the underlying 
breast cancer mortality between the screened and unscreened groups that had 
biased our results. To gain an insight into the direction of the bias, we first 
calculated the survival rate (Kaplan-Meier method) from diagnosis to death 
from breast cancer for the Nijmegen non-participant patients and compared it 
with that of Arnhem patients. Arnhem is a neighbouring city with a similar 
population size as in Nijmegen, where population screening for breast cancer 
was started in 1989. The cause of death of the Arnhem patients was deter-
mined in the same way as in Nijmegen. We selected patients aged 65 years or 
older at diagnosis who were diagnosed in 1977 to 1989. Figure 5.1 shows that 
the curve for the 99 Nijmegen non-participants was fairly similar to that of the 
372 Amhem patients. 
Next, we compared the incidence rate of breast cancer in Nijmegen with 
that in Amhem. In the period from 1 January 1979 (after the Nijmegen popu-
lation had undergone its first round of screening) to 31 December 1988, the 
incidence rate of breast cancer in Nijmegen equalled that in Arnhem (RR = 
0.97; 95% CI = 0.83-1.14). We used log-linear modelling with the computer 
package GLIM and adjusted for age in 5-year categories: 65-69, 70-74, 75-79, 
80-84 and 85 +. Subsequently, the Nijmegen population was restricted to non-
participants. For the Nijmegen non-participants compared with the Amhem 
population, the RR was 0.72 (95% CI = 0.56-0.93). In the participants, the 
incidence of breast cancer must have been much higher than in the non-partici-
pants. Therefore, we conclude that the bias had reduced the estimated mortal-
ity reduction; the real effect must have been larger. 
In a study on the survival of breast cancer patients, Satariano and Ragland49 
found that women with severe co-morbid conditions did not have a survival 
advantage because of early diagnosis. Death from other causes than breast 
cancer was the reason for this observation. We studied the overall survival 
rate from the date of invitation to round 3 (1979-80) in women aged 65-66 
years at this invitation, who had participated in round 2 (Kaplan-Meier 
method). Figure 5.2 shows that the women who participated in round 3 (n = 
720) had a far higher survival rate than those who did not (n = 198). Obvi-
ously, the participants had fewer co-morbid diseases or they were less severe. 
This means that the participants were at risk of dying from breast cancer for a 
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longer period. Moreover, we conclude that the women who chose to continue 
to participate in the screening are those who may benefit from a survival 
advantage because of early diagnosis. 
Figure 5.1 Breast cancer survival in 
Nijmegen non-participants and 
Arnhem patients 
Figure 5.2 Overall survival of women 
screened at age 63-64 years 
and invited at age 65-66 years 
90% 
704 
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2.5 5 7.5 10 
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50% 
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Classification of the cause of death of deceased breast cancer patients is 
difficult. Especially in elderly women, some degree of misclassification is 
unavoidable because of the presence of co-morbid conditions, including other 
malignancies. In many patients, the origin of newly diagnosed metastases was 
not confirmed histologically. Autopsy had been performed in 11% of the 
deceased patients only. This means that a new malignancy for example of the 
lung, may have been misdiagnosed as metastases originating from the breast 
cancer.
50
 To avoid different misclassification for screened and unscreened 
patients, the classification procedure was blinded for screening history. 
Misclassification that occurs independently of the screening history may have 
reduced the estimated mortality reduction. 
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Conclusion 
We conclude that continuing breast cancer screening after the age of 65 years, 
at least up to 75 years, will lead to a reduction in breast cancer mortality in 
elderly women. No effect of screening after 75 years was found, but only 8% 
of these women had participated regularly. However, the extent of harmful 
side effects of breast cancer screening increases with increasing age. Because 
the overall death rate is higher, some screen-detected patients may even die 
before the tumour would have become detectable clinically. The magnitude of 
both the effects and the side-effects of continued mammographie screening 
after 65 years of age need to be evaluated. As a reduction in breast cancer 
mortality of 45% can be achieved in women over age 65 years, it seems 
unfair to exclude these women from national screening programmes. A policy 
of screening elderly women free of charge if they request it, as is the case in 
the UK, seems preferable to excluding them totally. 
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Discussion 
Contrasted screening histories 
There was remarkable correspondence between the results of the two case-
referent studies, although the contrasted screening histories were different. All 
the study subjects had been invited at least twice in the first case-referent 
study, and at least once in the second study. In the first study, the women who 
participated in the index screening (just before the diagnosis of breast cancer 
in the case) were contrasted with those who did not. Previous participations 
were not taken into consideration. In the second study, contrast was made 
between women screened regularly (i.e. at the index screening and 2 years 
prior to that) and those who had not been screened in the previous 10 years 
(regardless of the number of previous invitations). This definition of regular 
screening, which involved the fewest possible screening rounds, guaranteed 
that in the regularly screened patients, breast cancer had been diagnosed at the 
earliest possible stage. The reference category was designed to reflect breast 
cancer mortality in a population from an area without a screening programme. 
In the first study, the ratio of the breast cancer mortality rates (RR) was 
0.58 (95% CI = 0.24-1.41); in women aged 65-74 years, RR = 0.34 (95% 
CI = 0.12-0.97) and in women aged 75 or older, RR = 2.87 (95% CI = 
0.62-13.2). The results in the second study were RR = 0.56 (95% CI = 
0.28-1.13); in those aged 65-74 years, RR = 0.45 (95% CI = 0.20-1.02) and 
in those aged 75 years, RR = 1.05 (95% CI = 0.27-4.14). 
Bias due to self-selection 
Case-referent studies may produce biased results because the contrasted popu-
lations, i.e. the screened and unscreened women, may differ in terms of the 
baseline risk of death from breast cancer.51·52 Because each woman makes her 
own choice about whether or not to participate, these self-selected populations 
may differ with regard to several unknown factors related to a woman's risk 
of dying from breast cancer. These unknown confounders may be either deter-
minants of breast cancer incidence (risk factors for the disease) or prognostic 
factors. In the two case-referent studies, analyses were performed that showed 
the presence of confounding due to self-selection, and specifically a higher 
underlying breast cancer mortality in the participants than in the non-partici-
pants. This bias diluted the reduction in breast cancer mortality and controlling 
for confounding would have increased the reduction. Other trials have also 
reported an increased breast cancer incidence in the participant population.53,54 
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Healthy screenee bias 
A specific source of bias has been called healthy screenee bias.52 Women with 
a previous negative screening test have a lower chance that breast cancer is 
present in the detectable preclinical phase than those not screened before. This 
form of bias needs to be taken into consideration when repeated participation 
is considered, as was the case in the second case-referent study in which a 
positive screening history was defined as participation in two screening 
rounds. To study the extent of healthy screenee bias, the ratio of the incidence 
rates of invasive breast cancer of women screened regularly relative to non-
participant women was calculated. The incidence rate in women screened 
regularly was calculated as the number of invasive cancers (both screen-
detected and interval cancers) per 1000 accepted invitations, whereas in non-
participants it was calculated as the number of invasive cancers per 1000 ref-
used invitations. In women aged 50-64, 65-69, 70-74 and 75 + , the ratios of 
the incidence rates in regular participants versus those in non-participants were 
1.3 (95% CI = 1.2-1.5), 1.8 (95% CI = 1.3-2.5), 2.0 (95% CI = 1.4-2.8) 
and 2.1 (95% CI = 1.4-3.0), respectively. The presence of "healthy screenee 
bias" would have resulted in rate ratios of smaller than 1. Presumably, the 
bias due to self-selection was much stronger than the bias due to the healthy 
screenee effect. 
Misclassification of the cause of death 
A form of bias that may have occurred is misclassification of the cause of 
death. Non-differential misclassification of the outcome may give biased 
results, especially if the outcome is rare.55 More precisely, screening may not 
be found to affect death from breast cancer even if screening reduces mortal-
ity. In the elderly, it is extremely difficult to make a correct classification of 
the cause of death. If metastases are diagnosed, the histological origin is not 
always verified. This leaves the possibility that metastases that were judged to 
originate from breast cancer, in fact had another origin, or may be a second 
primary cancer.50 In the Malmö trial that included women aged 45-70 years, 
193 breast cancer patients had breast cancer as the underlying cause of death 
according to the clinical information after 8 years of follow-up.5 Forty-one of 
these patients had at least one other malignancy, which was judged to be the 
cause of death in 31 of them. Autopsy had been performed on 26 of these 41, 
3 of whom appeared to have an additional previously unknown cancer as the 
cause of death, whereas 2 had died of the second malignancy. Between 1989 
and 1993, autopsy had been performed on 11% of the Nijmegen and Arnhem 
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patients, which involves a fairly large risk of misclassification of the cause of 
death. 
In order to evaluate misclassification of the cause of death in relation to age 
and screening history, a cross classification was made between the cause of 
death according to the death certificates, which were available for 640 Nijme-
gen and Arnhem patients who had died in the period 1975-1988, and the 
reviewed cause of death. The reviewed cause of death (breast cancer as under-
lying cause yes/no) was classified by a panel of physicians who were unaware 
of the screening history of the Nijmegen patients and was based on the clinical 
course of the disease and information about serious co-morbidity. Breast 
cancer was defined as the cause of death if the disease had progressed to 
distant sites and this progression was ultimately responsible for the death of 
the patient, or if in the presence of advanced disease other causes of death 
could be excluded. Patients with advanced breast cancer who died from other, 
unrelated causes were not classified as deaths from breast cancer. Table 5.6 
shows the sensitivity and specificity of the death certificates using the cause of 
death determined during the review, as the golden standard. The sensitivity 
was 91%, which means that 91% of the patients who had died from breast 
cancer according to the review also had breast cancer as the primary cause of 
death on their death certificate. The specificity was 83%, which means that 
17% of the patients who had died from another cause according to the review 
had breast cancer as the primary cause of death on the death certificate. It 
should be mentioned that although the reviewed classification of the cause of 
death was based on all the available clinical data it may have been inaccurate 
in an unknown proportion of the patients. 
Table 5.6 Cause of death on death certificate against reviewed cause of death 
Cause of death on death certifi-
cate 
Breast cancer primary cause 
Breast cancer secondary cause 
No breast cancer 
Total 
Death due to breast cancer at 
review 
Yes 
393(91%) 
9 ( 2%) 
29 ( 7%) 
431 (100%) 
No 
36 (17%) 
29 (14%) 
144 (69%) 
209 (100%) 
Total 
reviewed 
429 (66%) 
38 ( 6%) 
181 (28%) 
651 (100%) 
Sensitivity: 393/431 = 91% 
Specificity: 173/209 = 83% 
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The data were also analysed according to age at death because with increas-
ing age, an increase in co-morbidity may obscure the cause of death and lead 
to an increased misclassification. Table 5.7 shows the results of these analy-
ses. Sensitivity and specificity of the death certificate decreased slightly with 
increasing age. Nyström et al56 also reported more uncertainty about deter-
mining the reviewed cause of death in older women: the reviewers disagreed 
on the cause of death in 5% of the cases aged 40-59 years at randomization, in 
13% aged 60-69 and in 19% aged 70-74 years. In the UK trial, however, no 
relation was found between the accuracy of the cause of death on the death 
certificates and age.57 
Table 5.7 Sensitivity and specificity of death certificates according 
to age, screening history 
Determinant 
Age at death (yrs) 
35-59 
60-69 
70-79 
80+ 
Participation in 
yes 
no 
index screening 
Sensitivity 
94% (164) 
91 % (92) 
88% (93) 
88% (76) 
90% (91) 
91% (69) 
Specificity 
94% (16) 
83% (29) 
83% (66) 
81% (98) 
91 % (53)' 
77% (31)' 
In parentheses the denominator of the percentage 
' Difference in specificities = 14% (95%, CI = -4% to 30%) 
Another analysis was performed according to participation in the index 
screening (Nijmegen patients only) was performed because it was suspected 
that death from breast cancer may have been overreported in the screened 
population, in contrast with the unscreened population. If more cases of breast 
cancer are diagnosed, more deaths may be attributed to the disease in the 
screened population. The sensitivity of the death certificates, however, was 
identical, whereas the specificity was much lower in the non-participants (dif-
ference = 14%; 95% CI = -4% to 30%) than in the participants (Table 5.7). 
This means that there may have been overreporting of breast cancer deaths in 
the unscreened women. This decreased specificity may reflect the fact a larger 
proportion of the that non-participant patients had comorbid diseases which 
complicated the classification of the cause of death. The end-point used in the 
case-referent studies was the reviewed cause of death, which was probably 
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fairly accurate. However, it cannot be excluded with certainty that 
misclassification occurred more often in patients not screened at the index 
screening. If it were present, the proportion of patients who had died of other 
causes but had been classified as cases (i.e. death from breast cancer), may 
have been larger in the unscreened patients than in the screened patients, 
which would have overestimated the mortality reduction due to screening. 
Case-referent studies on screening efficacy 
A case-referent study may be a useful means to assess the efficacy of early 
detection and treatment for breast cancer.58 Several important aspects must be 
dealt with for the results to be valid, such as the definition of the cases and 
population referents,58·59 the definition of the relevant screening histories and 
last but not least, the elimination of bias due to self-selection.51"53 Bias due to 
misclassification of the cause of death is a problem that can occur in any study 
on the efficacy of screening with death as the end-point. 
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Abstract 
Recent case-referent studies in the Nymegen breast screening programme 
have shown a reduction in breast cancer mortality of approximately 50% 
due to screening of women aged 65 years and older. In this type of study, 
however, the results may be biased because of self-selection. The purpose 
of the study was to compare the breast cancer mortality rate in a popula­
tion invited for screening with that of a reference population from an area 
without a screening programme. 
In 1977-1978, 6773 women aged 68-83 years were enrolled in the 
mammographie screening programme in Nymegen, the Netherlands. The 
women were followed-up until 31 December, 1990. The reference popula­
tion consisted of women from the same birth cohort from Arnhem, a 
neighbouring city without mass screening, for whom the entry date was 1 
January, 1978. The ratios of the Nijmegen and Arnhem breast cancer 
mortality rates with 95% confidence intervals (CI) were calculated. 
In the study period, 173 patients were diagnosed with primary breast 
cancer in Nijmegen versus 183 in Arnhem; 40 Nijmegen patients had died 
of breast cancer versus 51 Arnhem patients. The cumulative mortality rate 
ratio was 0.80 (95% CI = 0.53-1.22). In the periods 1978-1981, 1982-1985 
and 1986-1990, the mortality rate ratios were 1.44 (95% CI = 0.67-3.10), 
0.81 (95% CI = 0.37-1.79) and 0.53 (95% CI = 0.27-1.04), respectively. 
After adjustment for the difference in incidence rate that existed 
between the Nijmegen and Arnhem populations, mammographie screening 
of women older than 65 can be expected to yield a 40 per cent reduction 
in breast cancer mortality after 10 years. 
Introduction 
Unlike most malignancies, the course of breast cancer can be altered by early 
detection and treatment. In women over the age of 50 years, trials have shown 
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a reduction of breast cancer mortality of some 25 to 30% in populations that 
were offered screening versus unscreened populations.1"4 The screening inter-
vals used in these studies ranged form 12-33 months and the screening test 
consisted of one or two view mammography, sometimes in combination with 
physical examination. 
More recently, a reduction in mortality has been demonstrated in women up 
to the age of 75 years.57 The results of the Swedish two-county study, which 
was a randomized trial, showed a decrease in breast cancer mortality due to 
the screening of women aged 65-74 years at entry.7 After 14 years of follow-
up, a statistically significant 32% reduction in the risk of death from breast 
cancer was observed in the population invited for screening. In Nijmegen, two 
case-referent studies included women aged 65 years and older at the index 
invitation {i.e. the most recent invitation to screening just prior to the diag-
nosis of breast cancer in the case). The estimated reductions in breast cancer 
mortality in women screened at the index invitation relative to those 
unscreened at that time were 42% and 44% after 13 and 18 years of follow-
up, respectively.5·6 There has been debate, however, on the validity of case-
referent studies as a method to evaluate screening efficacy, because the results 
may be biased due to self-selection for screening.8·9 The present study used an 
external reference population to evaluate whether including elderly women in a 
screening programme affects breast cancer mortality. 
Study population and methods 
In 1975, a breast cancer screening programme was started in the city of 
Nijmegen, the Netherlands.10 Initially, women born between 1910-1939 (aged 
35-66 years) were invited for one-view mammography. Since the second 
round of screening, 1977-1978, women bom before 1910, aged 67 years and 
older at their first invitation, have also been invited biennially to participate in 
the screening. The present study included all Nijmegen women born between 
1895-1909 who had been invited to screening before the end of 1990. In this 
way, 6773 women entered the screening programme in round 2, while 488 
women, who had come to live in Nijmegen after round 2, joined the 
programme between 1979 and 1990. 
Information about invitation and participation of the invited women was 
stored in a computer file. With the aid of the local authorities, follow-up could 
be recorded. All the patients diagnosed with breast cancer (screen-detected and 
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clinically diagnosed) at either of the two Nijmegen hospitals were registered at 
the Department of Radiology of the University Hospital. Clinical information 
about deceased patients was obtained from their medical files and reviewed by 
a panel of physicians who were unaware of the screening history of the 
patients. The cause of death was ascertained based on the clinical course of the 
disease and information about any serious co-morbidity. Breast cancer was 
defined as the cause of death if the disease had progressed to distant sites and 
this progression could not be ruled out as the cause of death of the patient. 
The reference population consisted of inhabitants of Arnhem, a city located 
20 kilometres north of Nijmegen, where mass screening was started in 1989 
for women aged 50-69 years as part of the national programme in the Nether-
lands. The Arnhem patients were registered by the "Carcinoma Work Group", 
which operated until 1991. With the aid of the local authorities, patients who 
had died or moved away from Arnhem could be identified. The cause of death 
of deceased patients was established in the same manner as that described 
above and by the same physicians as in Nijmegen. 
For Arnhem, person-years of observation had to be calculated from the 
official census statistics published annually by the Dutch Central Bureau of 
Statistics. These statistics keep track of the number of inhabitants of each sex, 
by year of birth, on 1 January of each calendar year. Although data for 
Nijmegen were available on an individual basis woman-years were also calcu-
lated on the basis of the census statistics for the sake of comparability of the 
information. For each calendar year up to and including 1990, the mid-year 
population size was calculated as the number of woman-years of observation 
in that year. 
Breast cancer mortality rates in Nijmegen were based on data from patients 
in whom breast cancer had been diagnosed after the invitation to the first 
round of screening in 1977-1978. For 1977 and 1978, a population-time 
correction was made according to the exact entry dates. The mortality rates in 
Arnhem were based on data from patients diagnosed from 1 January, 1978 
onwards, because this was close to the median date of the first invitation for 
the Nijmegen population (55% had been invited by then). Patients diagnosed 
with breast cancer before this date were excluded from the analysis. The ratio 
of the cumulative breast cancer mortality rates {i.e. number of breast cancer 
deaths in the entire study period divided by the total number of woman-years) 
was calculated, as well as the ratios of breast cancer mortality rate over three 
periods. Confidence intervals were calculated using the method based on the 
standard deviation of the log-transformed point estimates.11 
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Results 
In Nijmegen, 7261 women bom between 1895-1909 had been invited for 
screening in the period 1977-1990. A total of 46% had participated in the 
screening programme at least once and half of these women had taken part 
more than once. A marked decrease in the participation rate was observed as 
the round number and age increased, which is illustrated in Figure 6.1 for 
rounds 2, 5 and 8. In rounds 2-8, the overall participation rates were 43%, 
29%, 22%, 15%, 12%, 10% and 4%, respectively. 
Figure 6.1 Participation rate according to age at invitation for screening rounds 2,5 
and 8 
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In Nijmegen, 173 patients were diagnosed as having breast cancer, versus 
183 in Arnhem. Breast cancer had been diagnosed in Nijmegen: (1) after a 
positive screening examination in 57 patients, (2) after a negative screening 
mammogram (interval cancer) in 21 patients, (3) before the first invitation in 4 
patients who had moved to Nijmegen after 1977, and (4) after a refused invita­
tion in 91 non-participant cases. 
Table 6.1 shows the number of patients who had died from breast cancer as 
well as the woman-years of observation for each calendar year. Two deaths 
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occurred in patients diagnosed before their first invitation who had moved to 
Nijmegen after 1978. For both populations, the breast cancer mortality rates 
(5-year moving average) are displayed in Figure 6.2. Up to 6 years after the 
start of screening, the breast cancer mortality rate in Nijmegen was higher 
than that in Amhem. In the subsequent years, the Nijmegen breast cancer 
mortality rate stabilized, but an increase was observed in the late eighties. In 
Arnhem, the rate reached its maximum after 10 years and continued to 
decrease afterwards. 
Table 6.1 Number of breast cancer deaths and woman-years of observation by calen-
dar year and city 
Calendar 
year 
1978 
1979 
1980 
1981 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1977-1990 
breast 
cancer 
deaths' 
1 
1 
8d 
6d 
3 
4 
2 
2 
1 
3 
5e 
3f 
1 
40 
Nijmegen 
woman-
years 
6823c 
6248 
5947 
5620 
5284 
4967 
4669 
4378 
3988 
3567 
3224 
2944 
2656 
60313 
breast 
cancer 
deaths6 
1 
3 
1 
6 
1 
3 
6 
4 
9 
6 
6 
5 
0 
51 
Amhem 
woman-
years 
6502 
6222 
5961 
5725 
5455 
5155 
4836 
4494 
4174 
3863 
3526 
3156 
2765 
61832 
" only if diagnosed after first invitation in round 2 
* only if diagnosed after 31 December 1977 
c
 including 1977 
d
 including 1 death in patient diagnosed before enrollment, but after 
round! 
' including 1 death with breast cancer metastases 
!
 including 3 deaths with breast cancer metastases 
Cumulative mortality rate ratio 0.80 (95% CI = 0.53-1.22) 
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Figure 6.2 Breast cancer mortality rates (5-year moving average) in Nijmegen, if diag­
nosed after first invitation in 1977-1978, and in Arnhem, if diagnosed from 
1-1-1978 onwards 
Dealta per 1С? women-yean 
Arnhem 
Nijmegen 
Calendar year 
Table 6.2. Breast cancer deaths and woman-years in Nijmegen and Arnhem in three 
specified periods and the mortality rate ratio (95% CI) 
Period 
1978-1990 
1978-1981 
1982-1985 
1986-1990 
Nijmegen 
Deaths" 
16' 
16 
11 
13c 
Woman-
years 
60325 
24641 
19301 
16383 
Arnhem 
Deaths'1 
51 
11 
14 
26 
Woman-
years 
61845 
24415 
19943 
17487 
Mortality rate 
ratio (95% CI) 
0.80(0.53-1.22) 
1.44(0.67-3.10) 
0.81 (0.37-1.79) 
0 53(0 27-1.04) 
" if diagnosed after first invitation 
b
 if diagnosed from 1-1-1978 onwards 
r
 including 4 deaths with breast cancer metastases 
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Over the entire study period, the breast cancer mortality in Nijmegen was 
lower than that in Arnhem: cumulative mortality rate ratio = 0.80 (95% CI = 
0.53-1.22). Table 6.2 shows the ratio of the breast cancer mortality rates with 
95% CI over several periods. In the first period of four years, the mortality 
rate ratio was 1.44, in the second period of 4 years it was 0.81, whereas in 
the relevant observation period, 9 to 13 years after the start of screening, it 
was 0.53 (95% CI 0.27-1.04). 
Discussion 
According to the results, the effect of screening manifests itself approximately 
7 years after the start of the programme and reaches its maximum after about 
10 years. This is what one would expect if analyses only include patients in 
whom breast cancer was diagnosed after the start of the screening programme. 
The proportion of women who participated in the programme decreased grad-
ually, so the effect of screening on breast cancer mortality can also be 
expected to decrease gradually. It is likely that the effect will have diminished 
15-20 years after the start of screening. 
Could the observed mortality reduction be due to screening 46% of the 
population only, while half of these women had been screened at least twice? 
In an earlier study, the incidence of breast cancer in Nijmegen and Arnhem 
was compared in women aged 65 years and older. In the period 1979-1988, 
the incidence rate of breast cancer in Nijmegen (adjusted for age in 5-year 
categories: 65-69, 70-74, 75-79, 80-84 and 85+) equalled that in Arnhem (RR 
= 0.97; 95% CI = 0.83-1.14), whereas in the Nijmegen non-participants, the 
incidence was much lower than that in Arnhem (RR = 0.72, 95% CI = 0.56-
0.93). Therefore, the incidence of breast cancer in the participants must have 
been much higher than in the non-participants.6 We concluded that the women 
who do participate in the screening are at increased risk for breast cancer. As 
a consequence, actual participation may have a relatively large effect on breast 
cancer mortality in the population. 
An important question is whether the populations of Nijmegen and Arnhem 
would have had the same breast cancer mortality in the absence of screening. 
This cannot be derived directly, but it can be analysed using an indirect 
approach by comparing the incidence of breast cancer. For the period 1975-
1990, Figure 6.3 shows the incidence rates of primary breast cancer (5-year 
moving averages) in Nijmegen and Arnhem in women bom between 1895-
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1909. In almost every calendar year, the incidence in Nijmegen was lower 
than in Arnhem. It was only higher in Nijmegen in 1977-1981, when rounds 1 
and 2 took place for this birth cohort. In the early eighties, the incidence rate 
in Nijmegen declined, possibly due to the start of screening in the late 1970s. 
Figure 6.3 Breast cancer incidence rates (5-year moving average) in the Nijmegen and 
Arnhem populations born between 1895 and 1909 
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Table 6.3 shows the number of diagnosed patients and the woman-years of 
observation, as well as the incidence rate ratio for four periods. The incidence 
rate ratio was 0.90 (95% CI 0.75-1.07), adjusted for these 4 periods (directly 
weighted pooled estimate.12·13 Correction of the mortality rate ratio over the 
relevant observation period 1986-1990 gave an estimate of 0.59 (95% CI = 
0.30-1.16). 
Besides incidence, prognosis is also a modifier of breast cancer mortality. 
Differences in prognosis could result from differences in treatment between 
Nijmegen and Arnhem. In Nijmegen, 30% of the patients were diagnosed and 
treated at the University hospital, while the remainder were patients at the 
other Nijmegen hospital. At the latter hospital, a "Diagnostic Mamma Team" 
has been established, consisting of radiologists, pathologists and surgeons from 
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the two hospitals. Once a week, all the patients are discussed. The goal of 
these weekly discussions is to reduce the number of invasive diagnostic pro-
cedures. Although the patients from the 2 cities were treated according to 
protocols, the monitoring of diagnostic procedure may have influenced the 
decision for treatment. 
Table 6.3 Number of diagnosed breast cancer patients and woman-years in Nijmegen 
and Amhem in four specified periods and the incidence rate ratio (95% CI) 
Period 
1975-1976 
1977-1980 
1981-1985 
1986-1990 
1975-1990 
Nijmegen 
Diagnosed 
patients 
38 
84 
61 
43 
226 
Woman-
years 
14378 
25545 
24918 
16379 
81220 
Arnhem 
Diagnosed 
patients 
50 
71 
83 
53 
257 
Woman-
years 
14317 
25425 
25665 
17484 
82891 
Incidence rate 
' ratio (95% CI) 
0.76(0.50-1.15) 
1.18 (0.86-1.62) 
0.76 (0.54-1.05) 
0.87 (0.58-1.29) 
0.90* (0.75-1.07) 
* directly weighted pooled estimate12'3 
A difference may have existed in the extent of misclassification of the cause 
of death. The procedures followed and the criteria used to ascertain the cause 
of death were identical for the Nijmegen and Arnhem patients. However, the 
physicians who made the classification were not blinded for city. Although 
unlikely, this may have led to differential misclassification. It is also possible 
that the information available in Nijmegen was more extensive than in 
Arnhem, for instance due to the "Diagnostic Mamma Team". An indication 
that this may have been the case was the fact that 4 Nijmegen patients had 
been classified as "death from other cause with metastases of breast cancer", 
whereas no Amhem patients had been classified as such. This category was 
only used during the last 3 years. Previously, deaths had been classified as 
either "due to breast cancer" or "due to other causes". 
Several case-referent studies have been conducted in Nijmegen. In women 
aged 67 years or older at entry, breast cancer mortality after 6 years of fol-
low-up for those screened at least once was 19% lower (RR = 0.81, 95% CI 
0.23-2.75) than in those who had never been screened.14 In the study reported 
in 1994, the follow-up period was twelve years.5 In women aged 65 years and 
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older who had been invited for screening at least twice, breast cancer mortal-
ity in those who had participated in the most recent screening was 42% lower 
than in those who had rejected it (RR = 0.58, 95% CI 0.24-1.41). In those 
aged 65-74, the reduction in breast cancer mortality was 66% (RR = 0.34, 
95% CI 0.12-0.97). Coir most recent study on women aged 65 years and older 
after 17 years of follow-up showed that breast cancer mortality was 44% 
lower (RR = 0.56, 95% CI = 0.28-1.13) in women who had been screened 
regularly (i.e. after the two most recent invitations) than in women who had 
not been screened in the past 10 years.6 In women aged 65-74 years the reduc-
tion in breast cancer mortality was 55% (RR = 0.45, 95% CI 0.20-1.02). In 
these three case-referent studies, contrast was made between women who were 
screened and those who were not. The design of the present study was quite 
different, because contrast was made between the invited Nijmegen population, 
regardless of their actual screening history, and the uninvited Arnhem popula-
tion. The most important reason for this design was to avoid bias due to self-
selection. However, the price to be paid was a loss of contrast, because less 
than 50% of the invited population participated in at least one screening 
round. 
The Swedish two-county trial is the only other project with a long follow-up 
that included women aged 70 years and older. In that randomized study, the 
participation rate was 86% in women aged 65-69 and 77% in women aged 70-
74 years. Women of over 74 years were excluded from all the analyses, 
because of the low participation rate of approximately 50%. After 14 years, 
the ratio of the cumulative risk (i.e. number of deaths to the number of 
women enrolled) in the women aged 65-74 years at entry was 0.68 (95% CI 
= 0.51-0.89), which is much larger than in the Nijmegen invited population 
(cumulative rate ratio = 0.80). However, after the participation rate had been 
accounted for, the results compared very well. 
The results of the present study, although in themselves inconclusive 
because of the wide confidence intervals, show a reduction in breast cancer 
mortality in women who were older than 65 years at entry to the screening 
programme. After 10 years, the reduction in breast cancer mortality may be as 
large as 40%. 
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Review of the evidence 
Many reviews have addressed the effect of mammographie screening in 
women aged 50 to 70 years. The reduction in breast cancer mortality is 
reported to be approximately 30%.15 In the late 1980s and early 1990s, no 
evidence of an effect was evident in older women,2,6·7 because the number of 
elderly women included in the studies was too small. The goal of this thesis 
was to assess whether screening women aged 65 years and older has an effect 
on disease stage and breast cancer mortality. 
As expected on the basis of the review of the literature, mammographie 
screening of elderly women showed promising early results. In the Nijmegen 
project, breast cancer detection rates increased with increasing age but the 
tumours were being detected at a much more favourable stage, particularly in 
elderly women. The incidence of ductal carcinoma in situ (DCIS) was relative-
ly small. The participation rates, however, were very low. 
In the non-randomized Nijmegen screening project, the effect of screening 
on breast cancer mortality was initially assessed using the case-referent 
method. In screened women aged 65 years and older, after 14 and 19 years of 
follow-up, breast cancer mortality was 42% and 45% lower than in the 
unscreened women, respectively. Women were assigned to the "screened" 
group if they had participated in the programme in the relevant period, i.e. 
just before breast cancer had been diagnosed in the cases who died from breast 
cancer. The observed effect was somewhat stronger in women aged 65-74 
years at the most recent invitation, whereas it was absent in women of over 
74, probably due to the small number of women screened and to self-selection 
bias. Later on, these results were verified using the "intention-to-treat" 
analysis in which breast cancer mortality in the invited Nijmegen population of 
women of over 65 at their first invitation was compared to that in the unin-
vited Arnhem population. In the period 10 to 15 years after the start of the 
screening programme, breast cancer mortality in Nijmegen was 40% lower 
than in Amhem. 
Only one other screening project, the Swedish two-county trial, has included 
women aged 70 years and older.8 The analysis after 14 years of follow-up also 
showed a reduction in mortality due to screening. In women aged 65-74 years 
at entry, the ratio of the cumulative risk of death from breast cancer was 0.68 
(95% CI = 0.51-0.89). In women aged 65-69 years, it was 0.58 (95% CI = 
0.39-0.86) and in women aged 70-74 years, it was 0.78 (95% CI = 0.53-
1.20). The smaller effect of screening in the older age category could be 
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explained by a lower participation rate (77% compared to 86% in those aged 
65-69) and the smaller number of screenings that were offered (2 versus 4 in 
the younger women).9 The measure of effect in this study, the cumulative risk 
of dying from breast cancer, may not have been appropriate, because the mean 
follow-up in the invited population was 13.8 years, whereas it was 10.6 years 
in the control population.8 Calculation of the cumulative mortality rate ratio, 
which takes into account the difference in population time, produces 0.53 
(95% CI = 0.40-0.69) in women aged 65-74 years at entry, which indicates a 
stronger effect. If the participation rate of 80% is accounted for,5 the ratio of 
cumulative breast cancer mortality rates in the participants may be as small as 
0.41. This estimate compares very well with that in Nijmegen after 19 years 
of follow-up. In women aged 65-74 years at the index invitation, the mortality 
rate ratio was 0.45 (95% CI = 0.20-1.02). 
Randomized controlled trial 
The paradigm for studying the effectiveness of screening has been the random-
ized controlled trial.10"12 Bias due to self-selection is prevented by the random 
assignment of the study population to a group that is invited for screening and 
a group that is not, and analysis of the data according to the randomization 
groups, which will only differ in underlying breast cancer mortality due to 
chance. However, the experimental design has some problems of its own. A 
large study population and long follow-up time are required. Furthermore, 
participation will not be 100%, which dilutes the effect of screening on breast 
cancer mortality. In addition, women in the control population may be 
screened outside the study programme, which has been called "contamination" 
of the control population. 
In the Malmö trial, the breast cancer mortality risk ratio was 0.96 (95% CI 
= 0.68-1.35) after 8 years of follow-up, whereas in a case-referent analysis 
the rate ratio was 0.42 (95% CI = 0.22-0.78).10 The authors argued that the 
results of the case-referent design were biased due to self-selection. However, 
the relative risk estimate must have been biased also, because only 74% of the 
invited population actually participated and as many as 25% of the reference 
population had a mammogram outside the screening programme.10·13 
It will be extremely difficult to assess of the effect of screening in women 
aged 75 years and older. A randomized trial would be inefficient because the 
participation rates may be as low as 50%. It has been argued that because of 
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the low participation rates, screening will not further reduce breast cancer 
mortality in the general population. This is probably true, but an important 
question remains, Would women of older than 75 years who want to be 
screened, benefit from it? By not setting an upper age limit in the Dutch 
national screening programme insight could be obtained into the effect of 
screening after age 74 and early outcomes at least could be studied in a larger 
study population. In addition, a case-referent study could be set up nested 
within this screening programme. However, control of bias due to self-
selection would be difficult. Determinants of the incidence of breast cancer, 
i.e. risk factors for the disease, and determinants of the prognosis, i.e. the 
presence of prognostic comorbid conditions,14 would need to be measured, but 
it will be almost impossible to measure these confounding factors accurately in 
the non-participants. 
Gain in life expectancy 
In this thesis, the effect of screening on breast cancer mortality was studied. A 
50% reduction in breast cancer mortality in screened women does not mean 
that death is prevented in 50% of the women. Death can only be postponed 
and may eventually be due to other causes than breast cancer. It can be argued 
that the gain in life expectancy is a more appropriate outcome. In elderly 
women, with a relatively short life expectancy, a 50% reduction in breast 
cancer mortality in screened women may give only a marginal increase in life 
expectancy. 
Table 7.1 shows the hazard rate (proportion of women who will die in the 
next year) and the life expectancy for women at specific ages. An increasing 
hazard rate and a decreasing proportion of deaths attributed to breast cancer, 
indicate that the number of life years gained by participating in the screening 
will not be large in elderly women. However, the quality of life will be 
increased in patients who will not suffer from metastasized breast cancer. 
Preventing metastasized breast cancer may be a more appropriate goal of 
breast cancer screening in elderly women than preventing death from the 
disease. The outcome to be studied would then be the incidence of 
metastasized breast cancer instead of mortality from breast cancer. 
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Table 7.1 Life tables for women in the Netherlands (1994) 
Age in years Hazard rate" Years expected to live 
70.5 0.018 14.8 
75.5 0.032 11.2 
80.5 0.054 8.1 
85.5 0.102 5.6 
90.5 0.175 3.8 
95.5 0.290 2.6 
Modified from the CBS 
'proportion of deaths within the next year 
Future research 
Several issues for future research can be formulated. First, the quality of other 
screening modalities, e.g. palpation, should be studied. Breast self-examination 
is unlikely to form an alternative for mass screening.15 Regular physical breast 
examinations are not yet known to be an effective way of reducing breast 
cancer mortality,16 although in elderly women, the biological features that 
simplify the interpretation of mammography, i.e. the decreased proportion of 
parenchymal tissue and the increased proportion of fat, may also facilitate 
physical examination. Nevertheless, tumours detected by physical examination 
are generally larger than those detected by mammography. In a mixed group 
of symptomatic and asymptomatic breast cancer patients, only 18% of the 
mammographically detectable tumours of <10 mm could be detected by 
palpation by an experienced surgeon, whereas 74% of the tumours of 11-20 
mm and 96% of those of >20 mm were palpable.17 Only 19% of the in situ 
cancers were palpable. In elderly women, it is likely that a large proportion of 
very small cancers or in situ cancers would never become clinically relevant if 
undetected by mammographie screening. This means that the lower detect-
ability of these small tumours by physical examination may be an advantage. 
In the Canadian trial on women aged 50-59 years, after 7 years of follow-up 
the risk of dying from breast cancer in those who had been invited for annual 
mammography and physical examination was the same as that in the women 
who had only been invited for annual physical examination (RR = 0.97, 95% 
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CI = 0.62-1.52).18 The poor quality of the mammography technique has been 
suggested as the cause for the disappointing results.19 Another explanation may 
be that physical examination alone is just as effective as mammography plus 
physical examination for reducing mortality from breast cancer.20 After 10 or 
15 years of follow-up, this study should give clearer results on whether there 
is a reduction in mortality due to mammography in addition to physical 
examination. A study on the effect of screening with physical examination in 
women of older than 70 years, could be carried out within the Dutch national 
programme. Preferably, a comparison should be made with mammography 
screening. 
A further issue is whether the interval between screening examinations can 
be extended in women older than 70 years. An analysis of the incidence of 
breast cancer in relation to the time since the last screening in women who 
have reached the upper age limit, could be helpful. Finally, the extent of over-
diagnosis with mammographie screening should be studied, especially in the 
very elderly. If a large proportion of older screen-detected patients with a 
fairly indolent tumour are over-diagnosed and treated, then an upper age-limit 
should be set for breast cancer screening. As indicated previously, screening 
with physical examination instead of mammography may reduce the risk of 
overdiagnosis. 
Concluding remarks 
The findings in this thesis do not support the policy of the Dutch national 
breast screening programme to exclude women from screening after they have 
reached 70 years of age. A significant reduction in breast cancer mortality has 
been shown up to the age of 75, but there is no evidence that the reduction 
also extends to older women, because the number of elderly participants is too 
small and strong bias exists. It is possible, however, that women who choose 
to continue to participate may benefit up to the age of 85 years. First, these 
women have an increased risk of breast cancer compared to those who decide 
not to continue, and second, they have a longer than general life expectancy. 
Preferrably, women should be offered the opportunity to enroll for re-screen-
ing at the last planned screening examination, between 68-69 years of age. 
who show interest in being re-invited invited. 
The research questions formulated for older women could be addressed in 
the national screening programme. For this purpose, different screening 
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strategies could be followed at different screening centres, for example 
biennial one-view mammography, or triennial one-view mammography, or 
biennial physical breast examination. In this way, the remaining questions may 
be resolved within 10 years. 
References 
1. Hurley SF, Kaldor JM. The benefits and risks of mammographie screening for 
breast cancer. Epidemiol Rev 1992; 14: 101-30. 
2. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International 
Workshop on screening for breast cancer. J Natl Cancer Inst 1993; 85: 1644-56. 
3. De Koning HJ, Boer R, Warmerdam PG, Beemsterboer PMM, Van Der Maas PJ. 
Quantitative interpretation of age-specific mortality reductions from the Swedish 
breast cancer-screening trials. J Natl Cancer Inst 1995; 87: 1217-23. 
4. Kerlikowske K, Grady D, Rubin SM, Sandrock С, Ernster VL. Efficacy of 
screening mammography; a meta-analysis. J Am Med Assoc 1995; 273: 149-54. 
5. Day NE. Screening for breast cancer. Br Med Bull 1991; 47: 400-15. 
6. Morrison AS. Screening in Chronic disease. New York, Oxford University Press 
1992, second edition. 
7. Miller AB. Mammography screening guidelines for women 40 to 49 and over 65 
years old. Ann Epidemiol 1994; 4: 96-101. 
8. Chen H-Η, Tabar L, Fagerberg G, Duffy SW. Effect of breast cancer screening 
after age 65. J Med Screening 1995; 2: 10-4. 
9. Tabar L, Gad A. Screening for breast cancer: the Swedish trial. Radiology 1981; 
138: 219-22. 
10. Friedman DR, Dubin N. Case-control evaluation of breast cancer screening 
efficacy. Am J Epidemiol 1991; 133: 974-84. 
11. Gullberg B, Andersson I, Janzon L, Ranstam J. Screening mammography. Lancet 
1991; 337: 244. 
12. Moss SM. Case-control studies of screening. Int J Epidemiol 1991;20:1-6. 
13. Andersson I, Aspegren K, Janzon L, et al. Mammographie screening and mortality 
from breast cancer: the Malmö mammographie screening trial. Br Med J 1988; 
297: 943-8. 
14. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for 
the prognostic classification of cancer. Cancer 1996; 77: 834-42. 
15. Auvinen A, Elovainio L, Hakama M. Breast self-examination and survival from 
breast cancer. Breast Cancer Res Treat 1996; 38: 161-8. 
16. Mittra I. Breast screening: the case for physical examination without 
mammography. Lancet 1994; 343: 342-4. 
17. Reintgen D, Bergman C, Cox C, et al. The anatomy of missed breast cancers. Surg 
Oncol 1993; 2: 65-75. 
18. Miller AB, Baines CJ, Wall С Canadian National Breast Screening Study: 2. 
breast cancer detection and death rates among women aged 50-59 years. Can Med 
Assoc J 1992; 147: 1477-88. 
19. Kopans DB, Feig SA. The Canadian National Breast Screening Study: a critical 
review. Am J Radiol 1993; 161: 755-60. 
120 Chapter 7 
20. Baines CJ. The Canadian Breast Screening Study, a perspective on critisisms. Ann 
Intern Med 1994; 120: 326-34. 
Summary 121 
Summary 
Regular mammographie screening of women aged 50 to 70 years reduces 
breast cancer mortality. In older women, there is lack of evidence of such an 
effect. The goal of this thesis was to estimate whether including women of 65 
years and older in a screening programme affects disease stage and breast 
cancer mortality. The setting was the Nijmegen screening project for breast 
cancer, which was started in 1975 for approximately 23,000 women aged 35-
65 years. Since 1977, nearly 7,700 older women have also been invited for 
biennial screening with one-view mammography. 
The thesis starts with a review of the literature regarding epidemiological 
and biological factors that may influence the detection of breast cancer. In 
elderly women who do not undergo screening, breast cancer is diagnosed at a 
relatively late stage. In addition, a large proportion of older patients with 
advanced stage disease do not receive optimal therapy. The decreased propor-
tion of glandular tissue in the breasts of older women facilitates the detection 
of breast cancer by mammography. On the other hand, cancer-free breasts can 
be identified more easily, because benign breast diseases are fairly uncommon 
in older women. The tumour growth rate decreases with advancing age. 
Evidence from several sufficiently long-standing screening projects which also 
included elderly women have indicated a mortality reduction up to the age of 
75 years. 
The capability of detecting breast cancer with one-view mammography was 
studied by reviewing the previous negative screening mammogram of 44 
screen-detected patients and of 40 interval cancer patients. Thirteen per cent 
were classified as "screening error", 38% as "minimal sign present", 43% as 
"radiographically occult" and 6% as "radiographically occult at diagnosis". In 
this relatively small study, no difference in detectability was found between 
women aged 55-64 years and those 65-79. Future research may focus on a 
radiological analysis of "minimal sign" cases to find out whether the sensitiv-
ity can be improved without any significant decrease in the specificity. 
Further, computer-assisted reading of mammograms should be developed to 
help prevent screening errors and thus improve the sensitivity. A literature 
study was conducted to review the quality of one-view mammography com-
pared to two-view mammography for initial screening. With two-view 
mammography, the detection rate was estimated to increase by 24%, while at 
the same time the rate of recall for additional mammography views was 
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estimated to decrease by 15%. It was concluded that two-view mammography 
should be used for the first screening. 
In a study on age-specific early outcomes of the Nijmegen screening 
programme, decreasing rates of participation and increasing rates of breast 
cancer detection were found with increasing age. In women of over age 64 
who had been screened regularly, the incidence of breast cancer was approxi-
mately 2 times higher than that in non-participant women. This may mean that 
the women who continue to participate are at an increased risk for breast 
cancer. In addition, survival rates in these women were higher than in those 
who dropped-out. Another important finding was that for all age categories, 
tumours detected at screening were smaller and less often associated with 
axillary lymph node metastases than tumours diagnosed clinically. 
To determine whether screening after the age of 65 years affects breast 
cancer mortality, two case-referent studies and one non-randomized trial were 
performed. In the first case-referent study, with 14 years of follow-up from 
1975 to December 1988, the study population consisted of women who were 
65 years or older when they received their second invitation for screening. 
Thirty-three of these women died from breast cancer. For each of these cases, 
5 population referents were selected, matched for age and the number of 
previous invitations. The analysis showed that breast cancer mortality in the 
women who had participated in the most recent screening was 42% lower than 
in those who had not. The 95 % confidence interval (CI) of this reduction was 
0.28-1.41. In the age category 65-74 years, the reduction was 66% (rate ratio 
(RR) = 0.34; 95% CI = 0.12-0.97), whereas in women older than 74 years, 
mortality increased. 
In the second case-referent study, with an additional follow-up of 5 years, 
up to December 1993, the study population consisted of women who had been 
invited for screening at the age of 65 years or older. Eighty-two cases died 
from breast cancer; 410 referents were individually matched to the cases on 
age at invitation. In the women who had participated regularly (i.e., in the 2 
most recent screening rounds prior to diagnosis) breast cancer mortality was 
44% lower (RR = 0.56; 95% CI = 0.28-1.13) than in the women who had 
not participated. In those aged 65-74 years, the reduction in breast cancer 
mortality was 55% (RR = 0.45; 95% CI = 0.20-1.02), whereas a 5% 
increase was found in women aged 75 years and older (RR = 1.05; 95% CI 
= 0.27-4.14). 
An important limitation of case-referent studies is that mortality from breast 
cancer is studied in women who choose to be screened relative to those who 
Summary 123 
choose not to. These self-selected populations may differ with regard to the 
underlying risk of death from breast cancer. Several analyses showed that this 
bias had probably given an underestimation of the reduction in breast cancer 
mortality due to screening. In women aged 75 years and older, the bias may 
explain the increase in mortality in screened women. To verily the results of 
the case-referent studies, while avoiding bias due to self-selection, the Nijme-
gen programme was analysed according to the "intention to treat" principle 
used in clinical trials. Over the period 1978-1990, breast cancer mortality in 
the Nijmegen population, irrespective of participation in screening, was 
compared to that in the population of Arnhem, a neighbouring city without a 
screening programme. The analysis was restricted to women born between 
1895 and 1909, who were 68-83 years old at their first invitation for screen-
ing. In Nijmegen, 40 patients had died of the disease by the end of 1990, 
compared to 51 Arnhem patients. The ratio of the cumulative breast cancer 
mortality rates was 0.80 (95% CI = 0.53-1.22). In the relevant observation 
period 1986-1990, the breast cancer mortality rate ratio was 0.53 (95% CI = 
0.27-1.04), whereas it was 0.59 (95% CI = 0.30-1.16) after adjustment for 
the difference in incidence between the two populations. Restricting the bias 
due to self-selection in this way had a very high price. There was considerable 
loss of contrast between the study groups because only 46% of the Nijmegen 
population participated once or more in the screening. The result of this study, 
although in itself inconclusive, supports the findings of the case-referent 
studies. 
A problem in each of the studies was misclassification of the cause of death, 
as the histological origin of suspected metastases had not always been verified. 
If misclassification of the outcome occurs with equal frequency in the con-
trasted populations, then the estimated mortality reduction will be smaller than 
the real reduction due to screening. Unfortunately, the existence of differential 
misclassification of the cause of death, specifically a larger number of deaths 
from other causes that were attributed to breast cancer in the unscreened 
population, cannot be excluded with certainty. If it was present, 
misclassification bias may have exaggerated the reduction in breast cancer 
mortality. 
The overall conclusion is that mammographie screening after the age of 65 
years, at least up to 75 years, can reduce breast cancer mortality. In partici-
pants, breast cancer mortality can be up to 45% lower. Owing to the self-
selection of women at high risk and a longer than average life expectancy, 
screening may be beneficial up to the age of 85 years. However, the number 
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of life years gained in some of the screen-detected patients may only be 
marginal. In the elderly, increasing the quality of life by preventing life years 
lived with metastases of breast cancer may be a more appropriate goal of 
screening than a reduction in breast cancer mortality. 
Several issues may be of interest for future research. The quality of regular 
physical breast examination as a screening method is of particular importance 
for elderly women. The number of years that a patient would have to live with 
the knowledge that she has breast cancer if it is diagnosed by physical examin-
ation is much lower than with mammographie screening. It is unknown 
whether and to what extent screening with physical breast examination can 
reduce breast cancer mortality. Another issue is whether longer intervals 
between screening examinations can be used for older women. Furthermore, 
the extent of overdiagnosis with mammographie screening should be studied. 
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Resultaten van diverse onderzoeken hebben uitgewezen dat de sterfte aan 
borstkanker kan worden gereduceerd door vrouwen van 50 tot 70 jaar perio-
diek te screenen met mammografie. Onder de gescreende vrouwen kan de 
sterfte aan borstkanker met 45 % worden teruggedrongen. Het effect van scree-
ning op hogere leeftijd was onbekend. Het doel van de in dit proefschrift 
beschreven onderzoeken was het bestuderen van het effect van mammo-
grafische screening van vrouwen van 65 jaar en ouder op het stadium van 
borstkanker bij diagnose en op de sterfte aan borstkanker. De onderzoeken 
werden uitgevoerd binnen het kader van het Nijmeegse proefbevolkingsonder-
zoek naar borstkanker dat in 1975 van start ging. Circa 23000 vrouwen in de 
leeftijd van 35 tot 65 jaar werden eenmaal per twee jaar uitgenodigd een mam-
mogram te laten maken. Sedert 1977 werden ook ongeveer 7700 vrouwen 
ouder dan 65 jaar uitgenodigd deel te nemen. 
In Hoofdstuk 2 is een wordt een literatuurstudie weergegeven naar de epide-
miologische en biologische factoren die invloed kunnen hebben op de detectie 
van borstkanker. Voor oudere vrouwen die geen screening ondergaan, blijkt 
borstkanker doorgaans in een relatief vergevorderd stadium te worden gedia-
gnosticeerd. Bovendien krijgen oudere patiënten met gemetastaseerde borstkan-
ker vaker dan jongere patiënten minder zware therapie. Doordat de borsten 
van oudere vrouwen naar verhouding minder klierweefsel en meer vetweefsel 
bevatten, kan borstkanker relatief gemakkelijk worden opgespoord met behulp 
van mammografie. Bovendien komen goedaardige borstaandoeningen minder 
voor, waardoor de afwezigheid van borstkanker gemakkelijker kan worden 
vastgesteld. De groeisnelheid van borstkanker is lager op oudere leeftijd. 
Resultaten van een aantal screeningsprojecten met voldoende lange follow-up 
in verband met de lage groeisnelheid waarin ook ouderen tot de onderzoekspo-
pulatie behoorden, wijzen in de richting van een reductie in de borstkanker-
sterfte door screening tot aan de leeftijd van 75 jaar. 
In Hoofdstuk 3 is de kwaliteit van mammografie met één opname per borst 
voor het opsporen van borstkanker bestudeerd door de voorafgaande negatieve 
screeningsmammogrammen van 44 patiënten met een bij screening ontdekt 
carcinoom en 40 patiënten met een intervalcarcinoom (ontdekt in het scree-
ningsinterval na een negatief screeningsmammogram) opnieuw te beoordelen. 
Bij 13% van de patiënten bleken op het voorafgaande mammogram zeer sterke 
aanwijzingen voor borstkanker aanwezig te zijn ("fout bij screening"). Bij 
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38% van de patiënten was "een minimaal teken" zichtbaar dat slechts met 
kennis van de precieze localisatie in verband kon worden gebracht met de 
gediagnostiseerde borstkanker. Op 43% van de voorafgaande mammogrammen 
was geen enkel teken van borstkanker zichtbaar ("radiologisch occult"), terwijl 
in 6% van de gevallen noch het eerdere mammogram, noch het mammogram 
bij diagnose enig teken van kanker toonde ("radiologisch occult bij diagnose"). 
In dit onderzoek werd geen verschil in detectievermogen gevonden tussen de 
diverse leeftijdscategorieën. Nader onderzoek gericht op een grondige analyse 
van de groep met "minimale tekenen" werd aanbevolen om vast te stellen of 
de sensitiviteit van de mammografie kan worden verhoogd zonder een belang-
rijke verlaging van de specificiteit. Tevens werd de ontwikkeling aanbevolen 
van het gecomputeriseerd lezen van mammogrammen ter ondersteuning van de 
beoordeling door de radioloog, bij het detecteren van kanker. 
Bovendien staat in Hoofdstuk 3 een literatuuronderzoek beschreven naar de 
kwaliteit van mammografie met één opname per borst bij eerste screening in 
vergelijking met mammografie met twee opnames per borst. Door de tweede 
opname zou het detectiecijfer kunnen worden verhoogd met circa 24%, terwijl 
tegelijkertijd het percentage gescreenden zonder borstkanker bij wie aanvul-
lend mammografisch onderzoek zou moeten worden verricht, zou afnemen. 
Geconcludeerd werd dat bij eerste screening twee mammografische opnames 
per borst dienen te worden gemaakt. Of een tweede mammografische opname 
ook bij vervolgscreening kwaliteitsbevorderendwerkt, is nog onbekend. 
Een onderzoek naar vroege uitkomsten van het screeningsprogramma wordt 
weergegeven in Hoofdstuk 4. Op hogere leeftijd was de deelnamegraad lager 
en het detectiecijfer van borstkanker hoger. In de groep regelmatige partici-
panten (d.w.z. tenminste tweemaal achtereenvolgens gescreend) ouder dan 64 
jaar was de incidentie van borstkanker circa tweemaal zo hoog als onder non-
participanten van dezelfde leeftijd. Dit zou kunnen betekenen dat participanten 
die blijven deelnemen een verhoogd risico op borstkanker hebben. Bovendien 
was de overleving voor deze vrouwen langer dan voor participanten die 
ophielden deel te nemen. Een andere belangrijke bevinding was dat in alle 
leeftijdscategorieën de bij screening ontdekte tumoren kleiner waren en minder 
vaak uitzaaiingen naar de okselklieren vertoonden dan klinisch gediagnostiseer-
de tumoren. 
Om het effect van screening na de leeftijd van 65 jaar op de sterfte aan 
borstkanker te onderzoeken, werden twee patiënt-controle onderzoeken 
(Hoofdstuk 5) en een vergelijking van populaties (Hoofdstuk 6) uitgevoerd. In 
het eerste patiënt-controle onderzoek, met 14 jaar follow-up van 1975 tot en 
Samenvatting 127 
met december 1988, bestond de onderzoekspopulatie uit vrouwen die tenmin-
ste 65 jaar waren toen zij hun tweede uitnodiging ontvingen voor deelname 
aan de screening. Drieëndertig van deze vrouwen bleken te zijn overleden aan 
borstkanker en vormden de patiëntengroep. Bij elke patiënt werden 5 controles 
gezocht met identieke leeftijd bij de laatste uitnodiging voor de diagnose van 
borstkanker in de patiënt en met een gelijk aantal voorafgaande uitnodigingen. 
De resultaten lieten een reductie in de sterfte aan borstkanker zien van 42% 
voor de groep vrouwen die aan de meest recente uitnodiging gehoor hadden 
gegeven, vergeleken met de vrouwen die niet recent waren gescreend (rate 
ratio (RR) = 0,58; 95% betrouwbaarheidsinterval (BI) = 0,24-1,41). In de 
leeftijdscategorie 65-74 jaar was de reductie 66% (RR = 0,34; 95% BI = 
0,12-0,97), terwijl voor vrouwen ouder dan 74 jaar een toename in de 
borstkankersterfte werd gezien. 
Het tweede patiënt-controle onderzoek omvatte 5 extra jaren follow-up, nu 
tot en met december 1993. De onderzoekspopulatie bestond uit vrouwen die 
waren uitgenodigd voor deelname toen ze minstens 65 jaar oud waren. 
Tweeëntachtig patiënten waren aan borstkanker overleden. Bij elke patiënt 
werden 5 controles geselecteerd met identieke leeftijd bij de laatste uitnodiging 
voor de diagnose van borstkanker in de patiënt. Onder de vrouwen die 
regelmatig hadden deelgenomen (d.w.z. tenminste aan de twee meest recente 
screeningen) bleek de sterfte aan borstkanker 44% lager te zijn (RR = 0,56; 
95% BI = 0,28-1,13) dan onder de vrouwen die in de afgelopen 10 jaar niet 
waren gescreend. In de leeftijdscategorie 65-74 jaar was de reductie 55% (RR 
= 0,45; 95% BI = 0,20-1,02), maar in de leeftijd 75 jaar en ouder werd een 
toename van 5% gevonden (RR = 1,05; 95% BI = 0,27-4,14). 
Een belangrijke beperking van patiënt-controle onderzoeken is de mogelijk-
heid dat de resultaten vertekend zijn door zelfselectie. De groepen die worden 
vergeleken zijn namelijk de deelneemsters en niet-deelneemsters. De uitgeno-
digde vrouwen hebben zelf verkozen wel of niet aan het screeningsonderzoek 
deel te nemen. De aldus zelfgeselecteerde populaties kunnen verschillen ten 
aanzien van het onderliggende risico op sterfte aan borstkanker. Diverse 
analyses toonden aan dat de resultaten inderdaad waren vertekend. Indien 
echter voor deze vertekening gecorrigeerd had kunnen worden, zou de 
reductie in borstkankersterfte nog groter zijn geweest. Voor vrouwen van 75 
jaar en ouder kon de vertekening de toename in borstkankersterfte onder de 
gescreenden verklaren. 
De resultaten van de patiënt-controle onderzoeken werden geverifieerd in 
een studie volgens het in gerandomiseerde trials naar het effect van medische 
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interventie veel gebruikte "intention-to-treat" principe om vertekening door 
zelfselectie te voorkomen (Hoofdstuk 6). De sterfte aan borstkanker in de 
populaties van Nijmegen en Arnhem werd vergeleken over de periode 1978-
1990. Voor Nijmeegse vrouwen werd buiten beschouwing gelaten of ze daad-
werkelijk aan de screening hadden deelgenomen. In Arnhem was in deze 
periode geen screeningsprogramma. In de analyses werden alleen vrouwen 
beschouwd geboren in de jaren 1895-1909, die 68-83 jaar waren bij de eerste 
uitnodiging voor deelname aan de screening in Nijmegen. In de studieperiode 
bleken 40 Nijmeegse en 51 Arnhemse patiënten ten gevolge van borstkanker te 
zijn overleden. De reductie in de cumulatieve borstkankersterfte in de Nij-
meegse populatie was 20% (cumulatieve RR = 0,80; 95% BI = 0,53-1,22). 
In de relevante observatie periode 1986-1990 was de reductie 47% (RR = 
0,53; 95% BI = 0,27-1,04). Na correctie voor een verschil in incidentie 
tussen de populaties was de reductie 41% (RR = 0,59; 95% BI 0,30-1,16. In 
deze studie bleek dat het vermijden van de vertekening door zelfselectie ten 
koste ging van het contrast tussen de te vergelijken populaties, daar slechts 
46% van de Nijmeegse vrouwen tenminste eenmaal had deelgenomen aan de 
screening. Deze resultaten wijzen in dezelfde richting als die van de beide 
patiënt-controle onderzoeken. 
Een complicatie in elk van de onderzoeken was misclassificatie van de 
doodsoorzaak, daar het histologische origine van verdachte metastasen niet 
altijd werd geverifieerd. Bij een gelijke mate van misclassificatie in de te 
contrasteren populaties zal de reductie in borstkankersterfte in de studie 
worden onderschat; het werkelijke effect van screening zal groter zijn. Niet 
kon met zekerheid worden uitgesloten dat het percentage borstankerpatiënten 
overleden aan een andere oorzaak doch geclassificeerd als overleden aan 
borstkanker, groter was geweest in de non-participanten. Als dit daadwerkelijk 
het geval is geweest, kan de reductie in borstkankersterfte zijn overschat. 
De eindconclusie (Hoofdstuk 7) is dat mammografische screening na leeftijd 
65 jaar en tenminste tot aan 75 jaar, de sterfte aan borstkanker kan reduceren. 
Onder de participanten kan deze reductie zelfs 45% bedragen. Omdat ten 
gevolge van zelfselectie vrouwen blijven deelnemen die een relatief groot 
risico op borstkanker en een betrekkelijk lange levensverwachting hebben, zou 
screening zelfs op leeftijd 85 jaar nog een gunstig effect kunnen hebben. 
Echter, het aantal gewonnen levensjaren zou voor sommige patiënten met een 
bij screening ontdekte borstkanker slechts marginaal kunnen zijn. Op hogere 
leeftijd zou de toename in de kwaliteit van leven door het voorkomen van 
gemetastaseerde borstkanker een belangrijkere doelstelling van screening 
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kunnen zijn dan reductie in de sterfte aan borstkanker. 
In Hoofdstuk 7 worden tevens aanbevelingen gedaan voor aanvullend 
onderzoek. Periodiek lichamelijk borstonderzoek (palpatie) als screening-
methode zou met name van belang kunnen zijn voor oudere vrouwen, omdat 
door de relatief geringe aanwezigheid van klierweefsel detectie van borstkan-
ker met deze methode beter zou kunnen zijn. Onbekend is echter of, en zo ja 
in welke mate, screening middels palpatie de sterfte aan borstkanker kan 
reduceren. Een andere vraag is of voor oudere vrouwen een interval tussen de 
screeningsonderzoeken langer dan 2 jaar zou kunnen worden gebruikt. 
Tenslotte zou de mate van overdiagnostiek met mammografische screening 
kunnen worden onderzocht. 
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Stellingen 
behorend bij het proefschrift 
The efficacy of mammographie screening 
for breast cancer in elderly women 
1. Vrouwen dienen ook ná het bereiken van de leeftijd van 70 jaar de mogelijk-
heid te krijgen aan het landelijk bevolkingsonderzoek naar borstkanker deel 
te nemen, aangezien periodieke mammografïsche screening van oudere 
vrouwen leidt tot een vermindering van de borstkankersterfte (dit proef-
schrift). 
2. De lage deelnamegraad van vrouwen van 70 jaar en ouder is eerder een 
argument vóór dan tegen inclusie van deze leeftijdscategorie bij het landelijke 
bevolkingsonderzoek naar borstkanker, daar degenen die blijven deelnemen 
een verhoogde kans op borstkanker hebben (dit proefschrift). 
3. Bij vrouwen die voor het eerst deelnemen aan het bevolkingsonderzoek naar 
borstkanker dient het screeningsonderzoek te bestaan uit twee opnames per 
borst (dit proefschrift). 
4. De waarde van twee opnames per borst bij vervolgscreening is nog niet 
aangetoond, ook niet bij vrouwen met een dicht borstparenchym patroon. 
5. Agressieve screening, waarbij de nadruk op de sensitiviteit en minder op de 
specificiteit ligt, verdient in het geval van borstkanker geen voorkeur. 
6. Zelfselectie-bias is een vorm van confounding bias. 
7. De grote precisie van een onderzoeksresultaat is weinig zeggend indien de 
validiteit ervan niet vaststaat. 
8. Ouderschap dient niet alleen gericht te zijn op de beïnvloeding van de groei 
en ontwikkeling van kinderen, maar tevens op de groei en ontwikkeling van 
de ouders (Naar Thomas Gordon, Luisteren naar kinderen, 1979). 
9. De aarde is slechts één land waarvan wij allen burgers zijn (Bahâ 'ullah). 
10. Het leven is als een legpuzzel zonder voorbeeld. 
Jos van Dijck, 7 november 1996 



